STOCK TITAN

Mustang Bio puts 1-for-5 to 1-for-30 reverse split to vote

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
PRE 14A

Rhea-AI Filing Summary

Mustang Bio (MBIO) is asking stockholders to authorize a 1-for-5 to 1-for-30 reverse split of its issued and outstanding common stock, subject to approval. If approved, the board would choose the ratio and decide whether and when to act; it may implement the split before December 21, 2027, or abandon it.

Mustang says it received an additional period through April 12, 2027, to regain compliance with Nasdaq’s $1.00 minimum bid-price requirement. Regaining compliance requires a closing bid of at least $1.00 for 10 consecutive business days, generally no more than 20. The company cautions that the split may not lift the share price proportionately or improve liquidity. Authorized common shares would remain at 200,000,000, increasing the authorized but unissued shares available for future issuance and potential dilution.

At the December 21, 2026 virtual meeting, stockholders will also vote on seven director nominees, KPMG LLP’s appointment, and executive compensation. Manuel Litchman, M.D., President, Chief Executive Officer and Interim Chief Financial Officer, received total compensation of $498,263 for 2025; no annual cash incentive bonus was paid to preserve limited cash resources.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Moderate pointNasdaq bid-price deficiency has an April 12, 2027 compliance deadline.
Proposed reverse split ratio 1-for-5 to 1-for-30 Stockholder approval is requested; the board would determine the exact ratio.
Closing bid price $0.3909 per share Closing price on November 17, 2026, cited in an example of a 1-for-30 split.
Nasdaq minimum bid price $1.00 per share Bid Price Requirement for continued listing.
Compliance deadline April 12, 2027 Additional period to regain compliance with the Bid Price Requirement.
Common shares outstanding 6,738,693 shares As of November 17, 2026.
Class A common shares outstanding 845,385 shares As of November 17, 2026.
Manuel Litchman total compensation $498,263 2025; he is President, Chief Executive Officer and Interim Chief Financial Officer.
Authorized common shares 200,000,000 shares The number would remain unchanged after a reverse split.
Reverse Stock Split technical
"effect the Reverse Stock Split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Bid Price Requirement regulatory
"regain compliance with the Bid Price Requirement"
A bid price requirement is a rule that specifies the minimum price a buyer must offer per share when making an official purchase proposal, tender offer, auction bid, or similar transaction. It matters to investors because it sets a floor for negotiations and valuation—like a reserve price in an auction—ensuring bids meet regulatory, contract or market standards and helping shareholders and markets judge whether an offer is fair or likely to succeed.
Nasdaq Capital Market regulatory
"continue trading on the Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
broker non-vote regulatory
"which is a “broker non-vote”"
A broker non-vote happens when a brokerage firm holds shares in street name for a client but does not cast a ballot on a particular shareholder item because the broker lacks discretionary authority to vote that matter. Think of it like a person who owns a ticket but the ticket-holder refuses to vote on some issues; the share counts for ownership but not for that vote, which can affect whether proposals reach the required number of votes or a quorum.
controlled company regulatory
"we qualify as a “controlled company”"
A controlled company is a publicly traded firm where one shareholder or a small group holds enough voting power to determine board members and major strategic choices. For investors this matters because control can speed decision-making and protect long-term plans, but it also raises the risk that majority owners will favor their own interests over minority shareholders, reducing outside oversight—like a family-owned restaurant that sold shares but the family still calls the shots.
Say-On-Pay financial
"commonly known as a “Say-On-Pay” proposal"
A say-on-pay is a shareholder vote that gives investors a chance to approve or disapprove a company’s executive compensation packages, typically held at annual meetings. It matters because the vote signals investor satisfaction with how leaders are paid—like customers rating how well managers are rewarded—and can push boards to change pay plans, reducing governance risk and affecting investor confidence and stock value even though the vote is usually advisory rather than legally binding.
Name Total Compensation
Manuel Litchman, M.D. $498,263
Say-on-Pay Result Advisory vote on compensation of the named executive officer.
Key Proposals
  • Elect seven directors for one-year terms.
  • Ratify KPMG LLP as the independent registered public accounting firm for 2026.
  • Approve named executive officer compensation in an advisory vote.
  • Approve a reverse split amendment authorizing a 1-for-5 to 1-for-30 reverse split, with the board determining the ratio and whether and when to implement it.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What reverse split is Mustang Bio (MBIO) asking stockholders to approve?

Stockholders are being asked to approve a 1-for-5 to 1-for-30 reverse split; if approved, the board would select the exact ratio and decide whether and when to implement it.

When must MBIO regain Nasdaq’s bid-price compliance?

Mustang’s additional period to regain compliance ends April 12, 2027. It must show a closing bid price of at least $1.00 for 10 consecutive business days, generally no more than 20 consecutive business days.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001680048PRE 14Afalse00016800482024-01-012024-12-3100016800482023-01-012023-12-310001680048ecd:VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMemberecd:PeoMember2025-01-012025-12-310001680048ecd:EqtyAwrdsAdjsMemberecd:PeoMember2025-01-012025-12-310001680048ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMemberecd:PeoMember2025-01-012025-12-310001680048ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMemberecd:PeoMember2025-01-012025-12-3100016800482025-01-012025-12-31iso4217:USD

Table of Contents

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

SCHEDULE 14A

​

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

​

​

​

Filed by Registrant

☒

​

​

Filed by a Party other than the Registrant

☐

​

Check the appropriate box:

​

☒

Preliminary Proxy Statement

​

☐

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

​

☐

Definitive Proxy Statement

​

☐

Definitive Additional Materials

​

☐

Soliciting Material Under Rule 14a-12

​

MUSTANG BIO, INC.

(Name of Registrant as Specified in its Charter)

​

​

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

​

Payment of Filing Fee (Check the appropriate box):

​

☒

No fee required

​

☐

Fee paid previously with preliminary materials

​

☐

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

​

​

​

​

Table of Contents

​

PRELIMINARY PROXY STATEMENT – SUBJECT TO COMPLETION

Graphic

MUSTANG BIO, INC.

95 Sawyer Road, Suite 110

Waltham, Massachusetts 02453

Dear Stockholder:

You are cordially invited to the Annual Meeting of Stockholders (the “Annual Meeting”) of Mustang Bio, Inc. (“Mustang” or the “Company”), to be held virtually at 10:00 a.m. Eastern Time, on Monday, December 21, 2026. The Annual Meeting can be accessed by visiting www.virtualshareholdermeeting.com/MBIO2026, where you will be able to listen to the meeting live, submit questions and vote online. At the Annual Meeting, the stockholders will be asked to (i) elect seven directors for a term of one year, (ii) ratify the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2026, (iii) approve the compensation of our named executive officers, in an advisory vote, (iv) approve a form amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), to effect a reverse stock split of our issued and outstanding common stock (the “Reverse Stock Split”) within a range of between 1-for-5 and 1-for-30 (with our board of directors (the “Board”) being authorized to determine the exact ratio), and (v) transact any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting. You will also have the opportunity to ask questions at the meeting.

Your vote is important. It is important that your stock be represented at the meeting regardless of the number of shares you hold. To be sure your vote counts and assure a quorum, please vote by mobile device or over the Internet, or if you received proxy materials by mail, vote, sign, date and return the proxy card accompanying the printed proxy materials, as soon as possible, regardless of whether you plan to virtually attend the meeting; or if you hold your shares through a bank, brokerage firm or other nominee, please follow the instructions for voting provided by your bank, brokerage firm or other nominee, regardless of whether you plan to attend the meeting virtually. If you virtually attend the Annual Meeting and wish to vote virtually, you may revoke your proxy at the meeting.

If you have any questions about the proxy statement or the accompanying 2025 Annual Report, please contact us at info@mustangbio.com.

We look forward to seeing you at the Annual Meeting.

​

Sincerely,

​

​

​

​

​

​

Manuel Litchman, M.D.

​

President, Chief Executive Officer and Interim Chief Financial Officer

​

, 2026

Waltham, Massachusetts

​

Table of Contents

​

Graphic

MUSTANG BIO, INC.

95 Sawyer Road, Suite 110

Waltham, Massachusetts 02453

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

The Annual Meeting of Stockholders of Mustang Bio, Inc. will be held virtually on December 21, 2026, at 10:00 a.m., Eastern Time. At the Annual Meeting, stockholders will consider and act on the following items:

1.The election of seven directors for a term of one year;

​

2.The ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2026;

​

3.An advisory vote to approve the compensation of our named executive officers;

​

4.The approval of the form amendment to the Certificate of Incorporation to effect the Reverse Stock Split (the “Reverse Split Amendment”) and authorization of the Board, at its discretion, to effect the Reverse Stock Split, with such ratio to be determined by the Board in its discretion (the “Ratio”), for the primary purpose of regaining compliance with Nasdaq Listing Rule 5550(a)(2), which sets forth the minimum bid price requirement for continued listing on the Nasdaq Capital Market (the “Bid Price Requirement”); and

​

5.The transaction of any other business that may properly come before the Annual Meeting or any adjournment of the Annual Meeting.

​

Only those stockholders of record as of the close of business on November 17, 2026, are entitled to vote at the Annual Meeting or any postponements or adjournments thereof.  A complete list of stockholders entitled to vote at the Annual Meeting will be available for your inspection 10 days preceding our Annual Meeting, at our offices located at 95 Sawyer Road, Suite 110, Waltham, Massachusetts 02453, between the hours of 10:00 a.m. and 5:00 p.m., ET, each business day, or if we determine that a physical in-person inspection is not practicable, such list of stockholders may be made available electronically, upon request. You or your proxyholder may participate and vote by visiting www.virtualshareholdermeeting.com/MBIO2026 and using your 16-digit control number.

Please note the technical requirements for virtual attendance at the Annual Meeting, as described in the enclosed Proxy Statement under the heading “Questions and Answers.”

IMPORTANT NOTICE REGARDING AVAILABILITY OF PROXY MATERIALS. THIS PROXY STATEMENT AND THE ENCLOSED PROXY CARD ARE BEING MAILED TO OUR STOCKHOLDERS ON OR ABOUT                    , 2026. In accordance with the rules of the Securities and Exchange Commission (the “SEC”), we are advising our stockholders of the availability on the internet of our proxy materials related to our forthcoming Annual Meeting. Because we have elected to utilize the “full set delivery” option, we are delivering to all stockholders paper copies of all of the proxy materials, as well as providing access to those proxy materials on a publicly accessible website. This Notice of Annual Meeting and Proxy Statement are available to holders of our common stock at www.proxyvote.com and on our corporate website www.mustangbio.com.

​

Table of Contents

YOUR VOTE IS IMPORTANT!

Submitting your proxy does not affect your right to vote virtually if you decide to virtually attend the Annual Meeting. You are urged to submit your proxy as soon as possible, regardless of whether or not you expect to virtually attend the Annual Meeting. You may revoke your proxy at any time before it is voted at the Annual Meeting by (i) delivering written notice to our Corporate Secretary at our address above, (ii) submitting a later dated proxy card, (iii) voting again via the internet or (iv) attending the Annual Meeting and voting virtually. No revocation under (i) or (ii) will be effective unless written notice or the proxy card is received by our Corporate Secretary at or before the Annual Meeting.

When you submit your proxy, you authorize Manuel Litchman, M.D. and/or Peter Carney or their designees to vote your shares at the Annual Meeting and on any adjournments of the Annual Meeting in accordance with your instructions.

​

​

​

By Order of the Board of Directors,

​

_____________________________

​

​

​

​

​

Manuel Litchman, M.D.

​

President, Chief Executive Officer and Interim Chief Financial Officer

​

​

, 2026

Waltham, Massachusetts

​

​

​

​

​

Table of Contents

Table of Contents

​

​

QUESTIONS AND ANSWERS

2

CORPORATE GOVERNANCE

8

Our Board of Directors

8

Current Directors/Nominees

9

Communicating with the Board of Directors

11

Audit Committee

11

Compensation Committee

12

Nominating Process

12

Code of Business Conduct and Ethics

13

Insider Trading Policy; Policy Prohibiting Hedging and Speculative Trading

13

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FEES AND OTHER MATTERS

14

Audit Fees

14

Audit-Related Fees

14

Tax Fees

14

All Other Fees

14

Pre-Approval of Services

14

REPORT OF THE AUDIT COMMITTEE

16

OUR EXECUTIVE OFFICERS

17

EXECUTIVE COMPENSATION

18

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

24

DIRECTOR COMPENSATION

24

Director Compensation Program

24

Director Compensation Table

25

DELINQUENT SECTION 16(a) REPORTS

25

RELATED-PERSON TRANSACTIONS

26

STOCK OWNERSHIP OF OUR DIRECTORS, EXECUTIVE OFFICERS, AND 5% BENEFICIAL OWNERS

29

PROPOSAL ONE: ELECTION OF DIRECTORS; NOMINEES

31

PROPOSAL TWO: RATIFICATION OF APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

32

PROPOSAL THREE: ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS

33

PROPOSAL FOUR: APPROVAL OF THE REVERSE SPLIT AMENDMENT AND AUTHORIZATION OF THE BOARD TO DETERMINE THE RATIO AND EFFECT THE REVERSE STOCK SPLIT

34

ADDITIONAL INFORMATION

41

Householding of Annual Meeting Materials

41

Stockholder Proposals for Our 2027 Annual Meeting

41

Other Matters

41

Solicitation of Proxies

42

Incorporation of Information by Reference

42

APPENDIX A

43

​

​

​

​

​

i

Table of Contents

QUESTIONS AND ANSWERS

Q:

When is the Annual Meeting?

A.

The Annual Meeting will be held at 10:00 a.m., Eastern Time, on December 21, 2026.

Q:

Where will the Annual Meeting be held?

A.

The Annual Meeting will be held virtually by means of a live webcast, as further described herein, which can be accessed at www.virtualshareholdermeeting.com/MBIO2026 when you enter your 16-digit control number included with your proxy card.

Q:

What is the purpose of the Annual Meeting?

A.

At the Annual Meeting, our stockholders will act upon the matters outlined in the Notice of Annual Meeting of Stockholders accompanying this proxy statement, including (i) the election of seven directors for a term of one year, (ii) the ratification of the appointment of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2026, (iii) the approval of the compensation of our named executive officers, in an advisory vote, (iv) the approval of the Reverse Split Amendment and authorization of the Board, at its discretion, to determine the Ratio and effect the Reverse Stock Split, and (v) the transaction of any other business that may properly come before the Annual Meeting or any adjournment or postponement thereof.

Q.

Who is entitled to vote at our Annual Meeting?

A.

Only stockholders of record at the close of business on November 17, 2026, which we refer to as the Record Date, are entitled to receive notice of the Annual Meeting and to vote the shares that they held on that date at the Annual Meeting, or any adjournment or postponement thereof.  As of the close of business on the Record Date, we had 6,738,693 shares of common stock outstanding, 845,385 shares of Class A common stock outstanding (which converts to 1,127 shares of common stock), and 250,000 shares of Class A Preferred Stock outstanding (which converts to 333 shares of common stock).  Each share of common stock entitles its holder to one vote at the Annual Meeting, each share of Class A common stock entitles its holder to one-seven hundred fiftieth of one vote, and each share of Class A Preferred Stock entitled its holder to the number of votes that is equal to one and one-tenth times a fraction, the numerator of which is the sum of (A) the shares of outstanding common stock and (B) the whole shares of common stock into which the shares of outstanding Class A common stock and the Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock.  Our Amended and Restated Certificate of Incorporation provides that the holders of the Class A common stock are entitled to the number of votes equal to the number of whole shares of common stock into which the shares of Class A common stock held by such holder are convertible as of the Record Date. On April 3, 2023 and January 15, 2025, we effected reverse stock splits of our common stock. As a result, in accordance with the applicable provisions of our Certificate of Incorporation, each share of Class A common stock is entitled to one-seven hundred fiftieth of one vote. A list of stockholders entitled to vote at the Annual Meeting may be examined at our offices located at 95 Sawyer Road, Suite 110, Waltham, Massachusetts 02453, between the hours of 10:00 a.m. and 5:00 p.m., Eastern Time, each business day during the 10 days preceding the Annual Meeting, however, if we determine that a physical in-person inspection is not practicable, such list of stockholders may be made available electronically, upon request.

Stockholders of Record: Shares Registered in Your Name.  If on the Record Date your shares were registered directly in your name with our transfer agent, VStock Transfer LLC, then you are a stockholder of record.  As a stockholder of record, you may vote virtually at the Annual Meeting or vote by proxy.  Whether or not you plan to participate live during the Annual Meeting, we urge you to fill out and return the enclosed proxy card, to ensure your vote is counted.

​

2

Table of Contents

Beneficial Owner: Shares Registered in the Name of a Broker, Bank, Custodian or Other Nominee.  If on the Record Date your shares were held in an account at a brokerage firm, bank, custodian or other nominee, then you are the beneficial owner of shares held in “street name” and these proxy materials are being forwarded to you by that organization.  The organization holding your account is considered the stockholder of record for purposes of voting at the Annual Meeting.  As a beneficial owner, you have the right to direct your broker, bank, custodian or other nominee on how to vote the shares in your account.  You are also invited to attend the Annual Meeting.  However, because you are not the stockholder of record, you may not vote your shares virtually at the Annual Meeting unless you request and obtain a valid proxy from your broker, bank, custodian or other nominee.

Q:

How many votes do I have?

A.

On each matter to be voted upon, each holder of common stock has one vote for each share of common stock owned as of the Record Date; each holder of Class A common stock has one-seven hundred fiftieth of one for each share of Class A common stock owned as of the Record Date; and each holder of Class A Preferred Stock has the number of votes that is equal to one and one-tenth times a fraction, the numerator of which is the sum of (A) the shares of outstanding common stock and (B) the whole shares of common stock into which the shares of outstanding Class A common stock and the Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock, for each share of Class A Preferred Stock owned as of the Record Date.

Q:

How do I vote?

A.

You may vote prior to the Annual Meeting by following the instructions posted at www.proxyvote.com and entering your 16-digit control number included with the proxy card, via internet as directed the instructions on the proxy card, or by telephone as indicated in the proxy card.

Whether you hold shares directly as the stockholder of record or indirectly as the beneficial owner of shares held for you by a broker or other nominee (i.e., in “street name”), you may direct your vote without attending the Annual Meeting.  You may vote by granting a proxy or, for shares you hold in street name, by submitting voting instructions to your broker or nominee.  In most instances, you will be able to do this by internet, telephone or by mail.  Please refer to the summary instructions below and those included on your proxy card or, for shares you hold in street name, the voting instruction card provided by your broker or nominee.

By Internet - If you have internet access, you may authorize your proxy from any location in the world by following the instructions on the proxy card.

By Telephone - If you are calling from the United States or Canada, you may authorize your proxy by following the “By Telephone” instructions on the proxy card or, if applicable, the telephone voting instructions that may be described on the voting instruction card sent to you by your broker or nominee.

By Mail - You may authorize your proxy by signing your proxy card and mailing it in the enclosed, postage-prepaid and addressed envelope. For shares you hold in street name, you may sign the voting instruction card included by your broker or nominee and mail it in the envelope provided.

Alternatively, you may vote during the Annual Meeting by following the instructions posted at www.virtualshareholdermeeting.com/MBIO2026 and entering your 16-digit control number included with the proxy card.

Q:

What if I have technical difficulties or trouble accessing the virtual Annual Meeting?

A.

We will have technicians ready to assist you with any technical difficulties you may have accessing the virtual Annual Meeting.  If you encounter any difficulties accessing the virtual Annual Meeting during the check-in or meeting time, please call the technical support number located on the meeting page.  

​

3

Table of Contents

Q:

What is a proxy?

A.

A proxy is a person you appoint to vote your shares on your behalf.  If you are unable to attend the Annual Meeting, our Board is seeking your appointment of a proxy so that your shares may be voted.  If you vote by proxy, you will be designating Manuel Litchman, M.D. and Peter Carney our President, Chief Executive Officer and Interim Chief Financial Officer and Corporate Controller, respectively, as your proxies.  In such event, Dr. Litchman and Mr. Carney may act on your behalf and have the authority to appoint substitutes to act as your proxy.

Q:

How will my shares be voted if I vote by proxy?

A.

Your proxy will be voted according to the instructions you provide.  If you complete and submit your proxy but do not otherwise provide instructions on how to vote your shares, your shares will be voted (i) “FOR” the individuals nominated to serve as members of our Board, (ii) “FOR” the ratification of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2026, (iii) “FOR” the approval of the compensation of our named executive officers, in an advisory vote, and (iv) “FOR” the approval of the Reverse Split Amendment and authorization of the Board, at its discretion, to determine the Ratio and effect the Reverse Stock Split. Presently, our Board does not know of any other matter that may come before the Annual Meeting.  However, your proxies are authorized to vote on your behalf, using their discretion, on any other business that properly comes before the Annual Meeting.

Q:

Can I change my vote after I return my proxy card?

A.

Yes.  You may revoke your proxy at any time before the final vote at the Annual Meeting by:

If you are the record holder of your shares, you may revoke your proxy in any one of three ways:

●You may send a written notice that you are revoking your proxy to our Corporate Secretary, at our address above (so long as we receive such notice no later than the close of business on the day before the Annual Meeting);
●You may submit a later dated proxy card or by voting again via the internet as described herein; or
●You may attend the virtual Annual Meeting and notify the election officials at the Annual Meeting that you wish to revoke your proxy and vote live during the Annual Meeting by following the instructions posted at www.virtualshareholdermeeting.com/MBIO2026.  Simply attending the Annual Meeting will not, by itself, revoke your proxy.

If your shares are held by your broker, bank, custodian or other nominee, you should follow the instructions provided by such broker, bank, custodian or other nominee.

Q:

Is my vote confidential?

A.

Yes.  All votes remain confidential.

Q:

How are votes counted?

A.

Before the Annual Meeting, our Board will appoint one or more inspectors of election for the meeting.  The inspector(s) will determine the number of shares represented at the meeting, the existence of a quorum and the validity and effect of proxies.  The inspector(s) will also receive, count, and tabulate ballots and votes and determine the results of the voting on each matter that comes before the Annual Meeting.

​

4

Table of Contents

Q:

What is the effect of abstentions or broker non-votes?

A.

Abstentions and votes withheld, and shares represented by proxies reflecting abstentions or votes withheld, as well as “broker non-votes,” will be treated as present for purposes of determining the existence of a quorum at the Annual Meeting.  Abstentions and votes withheld are not votes cast “for” or “against” a proposal; however, their effect on the outcome of each proposal depends on the voting standard applicable to that proposal, as summarized in the table below. “Broker non-votes” occur when shares are held in street name and the broker submits a proxy, but does not cast a vote on a matter because the broker has not received voting instructions from the beneficial owner, and (i) the broker does not have discretionary voting authority on the matter or (ii) the broker chooses not to vote on a matter for which it has discretionary authority. Pursuant to the rules of the New York Stock Exchange (“NYSE”), which governs brokers’ use of discretionary authority, brokers are permitted to exercise discretionary voting authority only on “routine” matters when voting instructions have not been timely received from a beneficial owner.

For proposals not considered to be “routine” under NYSE rules, your broker, bank or other nominee cannot vote your shares on such proposals unless you provide to your broker, bank or other nominee voting instructions for each of these matters. If you do not provide voting instructions on a non-routine matter, your shares will not be voted on that matter, which is a “broker non-vote.”

Proposal

Vote Required

Effect of Abstentions / Withheld Votes

Effect of Broker Non-Votes

1.
Election of Directors

Plurality of the votes cast by the holders of shares present or represented by proxy and entitled to vote

No effect

No effect

2.
Ratification of KPMG LLP

Majority of the votes of the shares present or represented by proxy and entitled to vote on the subject matter

Same effect as a vote “AGAINST”

Not expected (routine matter)

3.
Say-on-Pay (advisory)

Majority of the votes of the shares present or represented by proxy and entitled to vote on the subject matter

Same effect as a vote “AGAINST”

No effect

4.
Reverse Split Amendment

Votes cast “FOR” exceed votes cast “AGAINST”

No effect

Not expected (routine matter)

​

Q:

What constitutes a quorum at the Annual Meeting?

A.

In accordance with Delaware law (the law under which we are incorporated), our Certificate of Incorporation, and our Amended and Restated Bylaws (our “Bylaws”), holders of a majority of the outstanding voting power of the Company, calculated in accordance with our Certificate of Incorporation, present in person or represented by proxy, constitute a quorum, thereby permitting the stockholders to conduct business at the Annual Meeting.  Abstentions, votes withheld, and broker non-votes will be included in the calculation of the number of votes for purposes of determining the existence of a quorum.

If a quorum is not present at the Annual Meeting, a majority of the stockholders present virtually and represented by proxy may adjourn the meeting to another date.  If an adjournment is for more than 30 days or a new record date is fixed for the adjourned meeting by our Board, we will provide notice of the adjourned meeting to each stockholder of record entitled to vote at the adjourned meeting.  At any adjourned meeting at which a quorum is present, any business may be transacted that might have been transacted at the originally called meeting.

​

5

Table of Contents

Q:

What vote is required to elect our directors for a one-year term?

A.

The affirmative vote of a plurality of the votes cast by the holders of shares present or represented by proxy and entitled to vote at the Annual Meeting is required for the election of each of the nominees for director.  “Plurality” means that the seven nominees receiving the largest number of votes will be duly elected as directors.  Abstentions, votes withheld, and broker or nominee non-votes will not affect the outcome of director elections.

Q:

What vote is required to ratify KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2026?

A.

The affirmative vote of a majority of the votes of shares present or represented by proxy and entitled to vote on the subject matter at the Annual Meeting is required to approve the ratification of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2026.  Abstentions will have the same effect as a negative vote.  Because the ratification of KPMG LLP as our independent registered public accounting firm for the year ending December 31, 2026 is considered a “routine” matter, brokers, banks and other nominees may vote uninstructed shares on this proposal.

Q:

What vote is required to approve the compensation of our named executive officers?

A:

The affirmative vote of a majority of the votes of shares present or represented by proxy and entitled to vote on the subject matter at the Annual Meeting is required to approve the compensation of our named executive officers, in an advisory vote. Abstentions will have the same effect as a negative vote.  However, broker non-votes will not have the effect of a vote against this proposal as they are not considered to be present and entitled to vote on this matter.

​

Q:

What vote is required to approve the Reverse Split Amendment and authorize the Board to determine the Ratio and effect the Reverse Stock Split?

​

A:

Pursuant to Section 242(d)(2) of the General Corporation Law of the State of Delaware (the “DGCL”), approval of Proposal Four requires that the votes cast "FOR" the proposal by the holders of our common stock, Class A common stock and Class A Preferred Stock, voting together as a single class, exceed the votes cast "AGAINST" the proposal. This voting standard is available because our common stock is listed on the Nasdaq Capital Market, and we expect our common stock to continue to meet Nasdaq's listing requirements relating to the minimum number of holders immediately after the Reverse Stock Split becomes effective. Abstentions will have no effect on the outcome of this proposal. Because Proposal Four is considered a "routine" matter, brokers, banks and other nominees may vote uninstructed shares on this proposal.

​

Q: Does any stockholder control the outcome of the vote?

​

A:

Yes. As of the Record Date, Fortress Biotech, Inc. (“Fortress”), our controlling stockholder, held all 250,000 outstanding shares of our Class A Preferred Stock and 536,577 shares of our common stock, representing approximately 56.2% of the total voting power of our outstanding capital stock entitled to vote at the Annual Meeting. Under our Certificate of Incorporation, the Class A Preferred Stock is entitled to a number of votes equal to one and one-tenth times the aggregate number of shares of common stock outstanding (including shares issuable upon conversion of the Class A common stock and the Class A Preferred Stock), so that the Class A Preferred Stock will at all times constitute a voting majority. As a result, Fortress has sufficient voting power to constitute a quorum and to approve each of the proposals to be voted on at the Annual Meeting, regardless of how other stockholders vote. Fortress has informed us that it intends to vote all of its shares “FOR” each of the director nominees and “FOR” Proposals Two, Three and Four.

Q:

How can I find out the results of the voting at the Annual Meeting?

A.

We will announce preliminary voting results at the Annual Meeting.  We will also disclose voting results in a Current Report on Form 8-K to be filed with the SEC within four business days after the Annual Meeting.

​

6

Table of Contents

Q:

What percentage of our outstanding common stock do our directors and executive officers own?

A.

As of November 17, 2026, our directors and executive officers owned, or have the right to acquire, less than one percent of our outstanding common stock. See the discussion under the heading “Stock Ownership of Our Directors, Executive Officers, and 5% Beneficial Owners” on page 29 for more details.

Q:

Who was our independent public accountant for the year ending December 31, 2025? Will they be represented at the Annual Meeting?

A.

KPMG LLP was the independent registered public accounting firm that audited our financial statements for the year ended December 31, 2025.  We expect a representative of KPMG LLP to be present at the Annual Meeting.

Q:Who is paying for this proxy solicitation?

​

A.

We will pay the entire cost of preparing, assembling, printing, mailing, and distributing these proxy materials and soliciting votes.  If you choose to vote over the internet, you are responsible for internet access charges you may incur.  If you choose to vote by telephone, you are responsible for telephone charges you may incur.  In addition to the mailing of these proxy materials, the solicitation of proxies or votes may be made in person, by telephone or by electronic communication by our directors, officers and employees, who will not receive any additional compensation for such solicitation activities.  Proxies also may be solicited by employees and our directors by mail, telephone, facsimile, e-mail or in person.

Q:

How can I obtain a copy of our Annual Report on Form 10-K?

A.

We have filed our Annual Report on Form 10-K for the year ended December 31, 2025 with the SEC.  The Annual Report on Form 10-K is also included in the 2025 Annual Report to Stockholders.  You may obtain, free of charge, a copy of our Annual Report on Form 10-K, including financial statements, by writing to our Corporate Secretary or by email at info@mustangbio.com.  Upon request, we will also furnish any exhibits to the Annual Report on Form 10-K as filed with the SEC.

​

​

7

Table of Contents

CORPORATE GOVERNANCE

Our Board of Directors

Our Bylaws provide that our Board shall consist of between one and nine directors, and such number of directors within this range may be determined from time to time by resolution of our Board or our stockholders. Currently, we have seven directors. The following individuals are being nominated to serve on our Board (See “Proposal One - Election of Directors; Nominees”):

​

​

​

​

​

Name

 

Age

 

Position(s)

​

Director Since

​

​

​

Manuel Litchman, M.D.

 

72

 

President, Chief Executive Officer, Interim Chief Financial Officer and Director

​

2017

​

​

​

Michael S. Weiss

 

60

 

Chairman of the Board of Directors and Executive Chairman

​

2015

​

​

​

Adam J. Chill

 

58

 

Director

​

2017

​

​

​

Neil Herskowitz

 

69

 

Director

​

2015

​

​

​

David Jin

​

36

​

Director

​

2024

​

​

​

Lindsay A. Rosenwald, M.D.

 

71

 

Director

​

2015

​

​

​

Michael J. Zelefsky, M.D.

 

66

 

Director

​

2017

​

​

​

​

The Board does not have a formal policy regarding the separation of the roles of Chief Executive Officer and Chairman of the Board, as the Board believes that it is in the best interests of the Company to make that determination based on the direction of the Company and the current membership of the Board. The Board has determined that having a director who is also the chief executive officer serve as the Chairman is not in the best interest of the Company’s stockholders at this time.

The Board held six meetings during the fiscal year ended December 31, 2025. Each incumbent director of the Company attended at least 75% of the aggregate of the total number of board meetings held during the period that director served, and the total number of meetings held by all board committees on which that director served during the period of that director’s committee service. Further, all directors attended last year’s annual meeting.

Mustang has a risk management program overseen by Manuel Litchman, M.D., our President, Chief Executive Officer and Interim Chief Financial Officer. Dr. Litchman and management identify material risks and prioritize them for our Board. Our Board regularly reviews information regarding our credit, liquidity, operations, and compliance as well as the risks associated with each.

The following biographies set forth the names of our directors and director nominees, their ages, the year in which they first became directors, their positions with us, their principal occupations and employers for at least the past five years, any other directorships held by them during the past five years in companies that are subject to the reporting requirements of the Securities Exchange Act of 1934 (the “Exchange Act”), or any company registered as an investment company under the Investment Company Act of 1940, as well as additional information, all of which we believe sets forth each director nominee’s qualifications to serve on the Board. There is no family relationship between and among any of our executive officers or directors. On April 7, 2017, we entered into an Executive Employment Agreement with Dr. Litchman, pursuant to which, among other things, the Company agreed to use its best efforts to cause Dr. Litchman to be nominated and reelected to the Board. Except as described herein, there are no arrangements or understandings between any of our executive officers or directors and any other person pursuant to which any of them are elected as an officer or director.

​

8

Table of Contents

Mustang adheres to the corporate governance standards adopted by The Nasdaq Stock Market LLC (“Nasdaq”). Nasdaq rules require our Board to make an affirmative determination as to the independence of each director. Consistent with these rules, our Board completed its annual review of director independence and considered relationships and transactions between each director or any member of his immediate family, on the one hand, and the Company and our subsidiaries and affiliates, on the other hand. The purpose of this review was to determine whether any such relationships or transactions were inconsistent with a determination that the director is independent. Based on this review, our Board determined that Adam Chill, Neil Herskowitz, and Michael Zelefsky, M.D., are independent under the criteria established by Nasdaq and our Board.

Fortress beneficially owns capital stock representing more than 50% of the voting power of our outstanding voting stock eligible to vote in the election of directors. As a result, we qualify as a “controlled company” under Nasdaq’s corporate governance rules, and we avail ourselves of certain “controlled company” exemptions. As a controlled company, we are not required to have a majority of “independent directors” on our Board as defined under Nasdaq rules, or have a compensation, nominating or governance committee composed entirely of independent directors. Despite qualifying as a controlled company, we have a separately constituted Compensation Committee consisting entirely of independent directors.

​

Current Directors/Nominees

Manuel Litchman, M.D. - President, Chief Executive Officer, and Director

Dr. Litchman has served as our President and Chief Executive Officer, and as a member of our Board since April 2017 and as Interim Chief Financial Officer since November 2024. Dr. Litchman has also served on the board of Cascade Prodrug, LLC, a private biotechnology company, since August 2025. Dr. Litchman joined us from Arvinas, LLC, where he served as President and Chief Executive Officer. While at Arvinas, Dr. Litchman oversaw the advancement of the company’s pipeline of protein-degradation therapeutics for the treatment of cancers and other diseases toward Investigational New Drug applications and secured multi-target discovery collaborations with Merck and Genentech. Prior to Arvinas, Dr. Litchman spent more than 18 years with Novartis Pharmaceuticals Corporation, where he held positions of increasing responsibility related to the development of Novartis’ oncology pipeline. Most recently, Dr. Litchman served as Senior Vice President and Executive Global Program Head, CTL019, Cell & Gene Therapies Unit, where he led a collaboration with the University of Pennsylvania investigating chimeric antigen receptor modified T cells (“CAR Ts”) directed against CD19 on B cell malignancies. Prior to the CTL019 collaboration, Dr. Litchman served as Novartis’ Vice President and Head, Oncology Business Development & Licensing.  Earlier in his career, Dr. Litchman was a senior equity analyst at Ursus Capital and directed oncology/immunology clinical research at Hoffmann-La Roche Inc. Dr. Litchman received his M.D. from Yale University School of Medicine, and his B.A. from Princeton University.  He completed his internal medicine residency and hematology-oncology fellowship at New York-Presbyterian/Weill Cornell Medical Center. Based on Dr. Litchman’s biotechnology and pharmaceutical industry experience and in-depth understanding of our business, we believe that Dr. Litchman has the appropriate set of skills to serve as a member of the Board.

Michael S. Weiss - Chairman of the Board of Directors and Executive Chairman

Mr. Weiss has served as Chairman of our Board since May 2015 and has also served as our Executive Chairman since January 2017. He previously served as our interim President & Chief Executive Officer from March 2015 to April 2017. He is also a board member and the Executive Vice Chairman, Strategic Development of Fortress Biotech, Inc., a position he has held since February 2014. He previously served as the Chairman of the board of directors of Checkpoint Therapeutics, Inc. prior to its acquisition by Sun Pharmaceuticals in May 2025. Since December 2011, Mr. Weiss has served in multiple capacities at TG Therapeutics, Inc., and is currently its Chairman, President and Chief Executive Officer. Mr. Weiss earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany. He began his professional career as a lawyer with Cravath, Swaine & Moore LLP. From 2002 to 2009, Mr. Weiss was the Chairman and Chief Executive Officer of Keryx Biopharmaceuticals, Inc. Additionally, Mr. Weiss co-founded and served as Co-Portfolio Manager and Managing Partner of Opus Point Partners, LLC from 2009 to 2019. Based on Mr. Weiss’s biotechnology and pharmaceutical industry experience, as well as his extensive management experience, we believe that Mr. Weiss has the appropriate set of skills to serve as a member of the Board.

9

Table of Contents

Effective January 1, 2017, our Board approved and authorized the execution of a Board Advisory Agreement with Caribe BioAdvisors, LLC (the “Advisor”), which is owned by Michael S. Weiss, to provide the Board with the advisory services of Mr. Weiss as Chairman of the Board and Executive Chairman. Pursuant to the Advisory Agreement, the Advisor is paid an annual cash fee of $60,000, in addition to any and all annual equity incentive grants paid to members of the Board.

Adam J. Chill - Director

Mr. Chill has served as a member of our Board since June 2017.  Mr. Chill is the President of and a Portfolio Manager at Kingsbrook Partners LP, an alternative asset management firm he co-founded in March 2009. From February 2001 to March 2009, Mr. Chill was a Portfolio Manager and Managing Director at Highbridge Capital Management, LLC, an alternative asset management firm owned by J.P. Morgan Asset Management. At Highbridge, Mr. Chill was responsible for structuring, negotiating and monitoring Highbridge’s portfolio of structured investments in public and private companies worldwide. From April 2000 to February 2001, Mr. Chill worked at Angelo, Gordon & Co., an alternative asset management firm. From October 1992 to April 2000, Mr. Chill was a corporate attorney specializing in securities and mergers and acquisitions at Stroock & Stroock & Lavan LLP. Mr. Chill is a co-founder of the Bayit Association of New Jersey. Mr. Chill received his B.A., magna cum laude, from Yeshiva University and his J.D. from Columbia University School of Law, where he was a Harlan Fiske Stone Scholar. Based on Mr. Chill’s extensive investment experience and knowledge of the biotechnology industry, we believe that Mr. Chill has the appropriate set of skills to serve as a member of the Board.

Neil Herskowitz - Director

Mr. Herskowitz has served as a member of our Board since August 2015. Mr. Herskowitz has served as the managing member of the ReGen Group of companies, located in New York, since 1998, which include ReGen Capital Investments LLC and Riverside Claims Investments LLC. He has also served as the President of its affiliate, Riverside Claims LLC, since June 2004. Mr. Herskowitz serves as a member of the board of directors for Avenue Therapeutics, Inc. and Journey Medical Corp. (both of which are Fortress partner companies), and previously served on the board of directors of Checkpoint Therapeutics, Inc. prior to its acquisition by Sun Pharmaceuticals in May 2025. Mr. Herskowitz received a B.B.A. in Finance from Bernard M. Baruch College in 1978. Based on Mr. Herskowitz’s financial industry experience and in-depth understanding of our business, we believe that Mr. Herskowitz has the appropriate set of skills to serve as a member of the Board.

David Jin - Director

Mr. Jin has served as a member of our Board since October 2024. Mr. Jin has served as the Chief Financial Officer of Fortress since August 2022 and Head of Corporate Development since May 2020. He also serves as Chief Operating Officer, Interim Chief Financial Officer and Corporate Secretary of Avenue Therapeutics, Inc. (a Fortress partner company) and as a member of the board of directors of Crystalys Therapeutics. Since August 2022, Mr. Jin has served as Treasurer of Fortress’ private subsidiaries, including Cyprium Therapeutics, Urica Therapeutics, Helocyte, and Cellvation. From March 2022 to August 2022, he served as Interim Chief Executive Officer at Avenue Therapeutics. Previously, he was on the investment team in the Private Equity & Real Assets group at Barings, Director of Corporate Development at Sorrento Therapeutics, Vice President of Healthcare Investment Banking at FBR & Co., and was in the management consulting group at IMS Health (now IQVIA). He holds a B.S. in Industrial Engineering & Management Sciences with a double-major in Mathematical Methods in the Social Sciences from Northwestern University. Based on Mr. Jin’s financial experience and knowledge of the biotechnology industry, we believe that Mr. Jin has the appropriate set of skills to serve as a member of the Board.

10

Table of Contents

Lindsay A. Rosenwald, M.D. - Director

Dr. Rosenwald has served as a member of our Board since our inception. Dr. Rosenwald has been a member of the board of directors of Fortress Biotech, Inc. since October 2009 and has served as its Chairman, President and Chief Executive Officer since December 2013. From November 2014 to August 2015, Dr. Rosenwald served as Interim President and Chief Executive Officer of Checkpoint Therapeutics, Inc. and remained on that company’s board of directors until its acquisition by Sun Pharmaceuticals in May 2025. He also serves on the board of directors of Avenue Therapeutics, Inc. and Journey Medical Corporation. Prior to that, from 1991 to 2008, he served as the Chairman of Paramount BioCapital, Inc. Over the last 30 years, Dr. Rosenwald has acted as a biotechnology entrepreneur and has been involved in the founding and recapitalization of numerous public and private biotechnology and life sciences companies. Dr. Rosenwald received his B.S. in finance from Pennsylvania State University and his M.D. from Temple University School of Medicine. We believe that Dr. Rosenwald’s extensive biotechnology, pharmaceutical and finance expertise, as well as his medical background and in-depth understanding of our businesses, makes him an exemplary candidate to continue serving on our Board.

Michael J. Zelefsky, M.D. - Director

Dr. Zelefsky has served as a member of our Board since June 2017. Dr. Zelefsky has served as a Member at NYU Langone since 2023 and before that was a Member at the Memorial Sloan-Kettering Cancer Center Department of Radiation Oncology since 2005. During his tenure at Memorial Sloan-Kettering, he served as Chief of Memorial Sloan-Kettering’s Brachytherapy Services since 2000 and was a Professor of Radiation Oncology at Weill Cornell Medical College, Cornell University since 1994. He is a recognized expert in radiation therapy and helped develop and enhance Memorial Sloan-Kettering’s prostate brachytherapy program. Dr. Zelefsky received a Bachelor of Arts in Biology (summa cum laude) from Yeshiva University in 1982 and a Medical Doctor degree from Albert Einstein College of Medicine in 1986. Dr. Zelefsky is currently Editor-in-Chief of Brachytherapy and has previously served as president of the American Brachytherapy Society. Based on Dr. Zelefsky’s extensive experience and background in oncology, we believe that Dr. Zelefsky has the appropriate set of skills to serve as a member of the Board.

Communicating with the Board of Directors

Our Board has established a process by which stockholders can send communications to the Board. You may communicate with the Board as a group, or to specific directors, by writing to our Corporate Secretary, at our offices located at 95 Sawyer Road, Suite 110, Waltham, Massachusetts 02453. The Corporate Secretary will review all such correspondence and regularly forward to our Board a summary of all correspondence and copies of all correspondence that, in the opinion of the Corporate Secretary, deals with the functions of the Board that he otherwise determines requires their attention. Directors may at any time review a log of all correspondence we receive that is addressed to members of our Board and request copies of any such correspondence. Concerns relating to accounting, internal controls, or auditing matters may be communicated in this manner, or may be submitted on an anonymous basis via e-mail at info@mustangbio.com. These concerns will be immediately brought to the attention of our Audit Committee and handled in accordance with procedures established by our Audit Committee.

Audit Committee

The Audit Committee currently consists of Adam J. Chill, Neil Herskowitz, and Michael J. Zelefsky, M.D. Mr. Chill chairs the Audit Committee.

The Audit Committee held four meetings during the fiscal year ended December 31, 2025. The duties and responsibilities of the Audit Committee are set forth in the Charter of the Audit Committee which was recently reviewed by our Audit Committee. A copy of the Charter of the Audit Committee is available on our website, located at ir.mustangbio.com. Among other things, the duties and responsibilities of the Audit Committee include reviewing and monitoring our financial statements and internal accounting procedures, the selection of, consultation with and review of the services provided by our independent registered public accounting and identifying and assessing any related party transactions in collaboration with counsel, accountants and management. Our Audit Committee has sole discretion over the retention, compensation, evaluation and oversight of our independent registered public accounting firm.

11

Table of Contents

The SEC and Nasdaq have established rules and regulations regarding the composition of audit committees and the qualifications of audit committee members. Our Board has examined the composition of our Audit Committee and the qualifications of our Audit Committee members in light of the current rules and regulations governing audit committees. Based upon this examination, our Board has determined that each member of our Audit Committee is independent and is otherwise qualified to be a member of our Audit Committee in accordance with the rules of the SEC and Nasdaq.

Additionally, the SEC requires that at least one member of the Audit Committee have a “heightened” level of financial and accounting sophistication. Such a person is known as the “audit committee financial expert” under the SEC’s rules. Our Board has determined that Mr. Chill is an “audit committee financial expert,” as the SEC defines that term, and is an independent member of our Board and our Audit Committee. Please see Mr. Chill’s biography under “Corporate Governance - Our Board of Directors” beginning on page 8 for a description of his relevant experience.

The report of the Audit Committee can be found on page 16 of this proxy statement.

Compensation Committee

The Compensation Committee currently consists of Adam J. Chill, Neil Herskowitz and Michael J. Zelefsky, M.D. Mr. Herskowitz chairs the Compensation Committee.

The Compensation Committee held one meeting during the fiscal year ended December 31, 2025. The duties and responsibilities of the Compensation Committee are set forth in the Charter of the Compensation Committee which was recently reviewed by our Compensation Committee. A copy of the Charter of the Compensation Committee is available on our website, located at ir.mustangbio.com. As discussed in its Charter, among other things, the duties and responsibilities of the Compensation Committee include approving any corporate goals and objectives relating to the compensation of our executive officers, evaluating the performance of our executive officers, and administering all of our executive compensation programs, including, but not limited to, our incentive and equity-based plans. The Compensation Committee evaluates the performance of all of our executive officers on an annual basis and reviews and approves on an annual basis all compensation programs and awards relating to such officers. The Compensation Committee applies discretion in the determination of individual executive compensation packages to ensure compliance with our compensation philosophy. Our Chief Executive Officer makes recommendations to the Compensation Committee with respect to the compensation packages for officers other than himself.

Nasdaq has established rules and regulations regarding the composition of compensation committees and the qualifications of compensation committee members. Our Board has examined the composition of our Compensation Committee and the qualifications of our Compensation Committee members in light of the current rules and regulations governing compensation committees. Based upon this examination, our Board has determined that each member of our Compensation Committee is independent and is otherwise qualified to be a member of our Compensation Committee in accordance with such rules.

Nominating Process

We do not currently have a nominating committee or any other committee serving a similar function. Although we do not have a written charter in place to select director nominees, our Board has adopted resolutions regarding the director nomination process. We believe that the current process in place functions effectively to select director nominees who will be valuable members of our Board.

We identify potential nominees to serve as directors through a variety of business contacts, including current executive officers, directors, community leaders and stockholders. We may, to the extent deemed appropriate by the Board, retain a professional search firm and other advisors to identify potential nominees.

​

12

Table of Contents

We will also consider candidates recommended by stockholders for nomination to our Board. A stockholder who wishes to recommend a candidate for nomination to our Board must submit such recommendation to our Corporate Secretary at our offices located at 95 Sawyer Road, Suite 110, Waltham, Massachusetts 02453. Pursuant to our Bylaws, any recommendation must be received not less than 50 calendar days nor more than 90 calendar days before the anniversary date of the previous year’s annual meeting.

We believe that our Board as a whole should encompass a range of talent, skill, and expertise enabling it to provide sound guidance with respect to our operations and interests. Our independent directors evaluate all candidates to our Board by reviewing their biographical information and qualifications. If the directors determine that a candidate is qualified to serve on our Board, such candidate is interviewed by at least one of the directors and our Chief Executive Officer. Other members of the Board also have an opportunity to interview qualified candidates. The directors then determine, based on the background information and the information obtained in the interviews, whether to recommend to the Board that the candidate be nominated for approval by the stockholders to fill a directorship. With respect to an incumbent director whom the directors are considering as a potential nominee for re-election, the directors review and consider the incumbent director’s service during his or her term, including the number of meetings attended, level of participation, and overall contribution to the Board. The manner in which the directors evaluate a potential nominee will not differ based on whether the candidate is recommended by our directors or stockholders.

We consider the following qualifications, among others, when making a determination as to whether a person should be nominated to our Board: the independence of the director nominee; the nominee’s character and integrity; financial literacy; level of education and business experience, including experience relating to biopharmaceutical companies; whether the nominee has sufficient time to devote to our Board; and the nominee’s commitment to represent the long-term interests of our stockholders. We review candidates in the context of the current composition of the Board and the evolving needs of our business. We believe that each of the current members of our Board (who are also our director nominees) has the requisite business, biopharmaceutical, financial or managerial experience to serve as a member of the Board, as described above in their biographies under the heading “Corporate Governance - Current Directors/Nominees.” We also believe that each of the current members of our Board has other key attributes that are important to an effective board, including integrity, high ethical standards, sound judgment, analytical skills, and the commitment to devote significant time and energy to service on the Board and its committees.

We do not have a formal policy in place with regard to diversity in considering candidates for our Board, but the Board strives to nominate candidates with a variety of complementary skills so that, as a group, the Board will possess the appropriate talent, skills and expertise to oversee our business.

Code of Business Conduct and Ethics

We adopted a Code of Ethics (the “Code”), which applies to all of our directors and employees, including our principal executive officer and principal financial officer. The Code includes guidelines dealing with the ethical handling of conflicts of interest, compliance with federal and state laws, financial reporting, and our proprietary information. The Code also contains procedures for dealing with and reporting violations of the Code. The Code is disclosed, and any amendments thereto, or any waivers of its requirements will be disclosed, on our website at www.mustangbio.com.

Insider Trading Policy; Policy Prohibiting Hedging and Speculative Trading

We have adopted an Insider Trading Policy that governs the purchase, sale, and other dispositions of our securities on the basis of material non-public information by directors, officers, employees, consultants and contractors. We believe these policies and procedures are reasonably designed to promote compliance with insider trading laws, rules and regulations, and applicable Nasdaq listing standards.

​

Pursuant to our Insider Trading Policy, our officers, directors, and employees are prohibited from engaging in speculative trading, including hedging transactions or short sale transactions with respect to Company securities.

​

​

13

Table of Contents

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FEES AND OTHER MATTERS

KPMG LLP, the independent registered public accounting firm that audited our financial statements for the year ended December 31, 2025, has served as our independent registered public accounting firm since September 2021. We expect a representative of KPMG LLP to be present at the Annual Meeting. The representative will have an opportunity to make a statement and will be available to answer your questions.

Our Board has asked the stockholders to ratify the selection of KPMG LLP as our independent registered public accounting firm. See “Proposal Two: Ratification of Appointment of KPMG LLP as Our Independent Registered Public Accounting Firm” on page 32 of this proxy statement. The Board has reviewed the fees described below and concluded that the payment of such fees is compatible with maintaining KPMG LLP’s independence. All proposed engagements of KPMG LLP, whether for audit services, audit-related services, tax services, or permissible non-audit services, were pre-approved by our Audit Committee.

Audit Fees

For the year ended December 31, 2025, KPMG LLP billed us an aggregate of approximately $413,000 in fees and professional services rendered in connection with the audit of our annual financial statements included in our Annual Reports on Form 10-K for the 2025 fiscal year, the review of our financial statements included in our Quarterly Reports on Form 10-Q during that fiscal year, and overages incurred for final billings for the 2024 audit.

For the year ended December 31, 2024, KPMG LLP billed us an aggregate of approximately $412,000 in fees and professional services rendered in connection with the audit of our annual financial statements included in our Annual Reports on Form 10-K for the 2024 fiscal year and the review of our financial statements included in our Quarterly Reports on Form 10-Q during that fiscal year.

Audit-Related Fees

For the year ended December 31, 2025, and 2024, KPMG LLP billed us an aggregate of approximately $293,000 and $255,000, respectively, in fees for audit-related services rendered in connection with securities offerings and registration statements, in addition to the fees described above under the heading “Audit Fees.”

Tax Fees

During the fiscal years ended December 31, 2025 and 2024 we were not billed by KPMG LLP for fees for professional services rendered for tax compliance, tax advice, and tax planning services.

All Other Fees

During the fiscal years ended December 31, 2025 and 2024, we were not billed by KPMG LLP for any fees for services, other than those described above, rendered to us for each of those fiscal years.

Pre-Approval of Services

Our Audit Committee has established a policy setting forth the procedures under which services provided by our independent registered public accounting firm will be pre-approved by our Audit Committee. The potential services that might be provided by our independent registered public accounting firm fall into two categories:

​

●Services that are permitted, including the audit of our annual financial statements, the review of our quarterly financial statements, related attestations, benefit plan audits and similar audit reports, financial and other due diligence on acquisitions, and federal, state, and non-US tax services; and

​

●Services that may be permitted, subject to individual pre-approval, including compliance and internal-control reviews, indirect tax services such as transfer pricing and customs and duties, and forensic auditing.

14

Table of Contents

​

Services that our independent registered public accounting firm may not legally provide include such services as bookkeeping, certain human resources services, internal audit outsourcing, and investment or investment banking advice.

​

All proposed engagements of our independent registered public accounting firm, whether for audit services or permissible non-audit services, are pre-approved by our Audit Committee. We jointly prepare a schedule with our independent registered public accounting firm that outlines services which we reasonably expect we will need from our independent registered public accounting firm and categorize them according to the classifications described above. Each service identified is reviewed and approved or rejected by our Audit Committee.

​

15

Table of Contents

REPORT OF THE AUDIT COMMITTEE

In monitoring the preparation of our financial statements, the Audit Committee met with both management and KPMG LLP, our independent registered public accounting firm for the year ended December 31, 2025, to review and discuss all financial statements prior to their issuance and to discuss any and all significant accounting issues. Management and our independent registered public accounting firm advised the Audit Committee that each of the financial statements was prepared in accordance with generally accepted accounting principles in the United States. The Audit Committee has discussed with KPMG LLP the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (PCAOB) and the SEC. The Audit Committee has also discussed the independence of KPMG LLP and has received from KPMG LLP the letter and written disclosures required by the applicable requirements of the PCAOB regarding its communications with the Audit Committee concerning independence.

Finally, the Audit Committee continues to monitor the scope and adequacy of our internal controls and other procedures, including any and all proposals for adequate staffing and for strengthening internal procedures and controls where appropriate and necessary. These measures include, without limitation, a quarterly review of related party transactions and relationships pursuant to regularly updated reports prepared by Fortress’ internal legal counsel and our principal financial officer.

On the basis of these reviews and discussions, the Audit Committee recommended to the Board the inclusion of our audited financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, for filing with the SEC.

​

​

​

By the Audit Committee,

​

​

​

​

Adam J. Chill, Chair

​

Neil Herskowitz

​

Michael J. Zelefsky

​

​

​

​

November 20, 2026

​

Waltham, Massachusetts

​

​

​

​

​

16

Table of Contents

OUR EXECUTIVE OFFICERS

Executive Officers

Our current executive officers are as follows:

​

​

​

​

​

​

​

Name

​

Age

​

Position

​

Executive Officer Since

Manuel Litchman, M.D.

​

72

​

President, Chief Executive Officer, Interim Chief Financial Officer and Director

​

2017

​

No executive officer is related by blood, marriage or adoption to any other director or executive officer.

Manuel Litchman, M.D. – President, Chief Executive Officer, Interim Chief Financial Officer and Director

Dr. Litchman’s biography is presented under “Corporate Governance – Current Directors/Nominees” on page 9 of this proxy statement.

​

17

Table of Contents

EXECUTIVE COMPENSATION

Summary Compensation Table

As determined in accordance with SEC rules, our “named executive officers” (“NEOs”) for purposes of this proxy statement are the individuals set forth below, which includes all executive officers serving during 2025. The following table sets forth information concerning compensation paid by us to our NEOs for their services rendered to us in all capacities during the years ended December 31, 2025 and 2024.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Non-Equity

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Stock

​

​

Option

​

​

Incentive Plan

​

​

All Other

​

​

​

​

​

​

​

​

Salary

​

Bonus

​

​

Awards (1)

​

​

Awards

​

​

Compensation

​

​

Compensation

​

​

Total

Name and Principal Position

  ​ ​ ​

Year

  ​ ​ ​

​

($)

  ​ ​ ​

($)

  ​ ​ ​

​

($)

  ​ ​ ​

​

($)

  ​ ​ ​

​

($)

  ​ ​ ​

​

($)

  ​ ​ ​

​

($)

Manuel Litchman, M.D.

​

2025

​

$

485,500

​

$

—

(2)​

$

—

​

$

—

​

$

—

​

$

12,763

(3)​

$

498,263

President, Chief Executive Officer and Interim Chief Financial Officer

​

2024

​

$

485,500

​

$

—

(2)​

$

—

​

$

—

​

$

—

​

$

12,542

(3)​

$

498,042

(1)The amounts in the “Stock Awards” column reflect the aggregate grant date fair value of restricted stock units granted during the year computed in accordance with the provisions of FASB ASC Topic 718. The assumptions used in calculating these amounts are incorporated by reference to Note 10 to the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2025.
(2)In 2025 and 2024, the Compensation Committee decided to not pay 2025 and 2024 annual cash incentive bonuses. See the “Annual Cash Incentive Bonus” section below for additional details.
(3)All other compensation for Dr. Litchman is comprised of Company matching 401(k) contributions.

18

Table of Contents

Narrative to Summary Compensation Table

Employment Agreements

Dr. Litchman

In April 2017, we entered into an employment agreement with Dr. Litchman, our President, Chief Executive Officer and Interim Chief Financial Officer, pursuant to which he received an initial annual base salary of $395,000. As part of his annual review in January 2023, the Board increased Dr. Litchman’s annual base salary to $485,500 effective as of April 1, 2023. There were no increases to Dr. Litchman’s annual base salary in 2025 and 2024. The employment agreement further provides eligibility for an incentive bonus linked to the realization of certain corporate milestones to be established annually by the Board or the Compensation Committee. Dr. Litchman’s target annual bonus is equal to fifty percent (50%) of his annual salary, and the Board or the Compensation Committee will determine the actual payout amount each year. Dr. Litchman’s annual bonuses for 2024 and 2025 are described under “Annual Cash Incentive Bonus” below. The employment agreement provides that if we terminate Dr. Litchman without cause or if he resigns for good reason, as those terms are defined in the employment agreement, he will be entitled to: (i) severance payments at a rate equal to his base salary then in effect for a period of 12 months following his termination date; (ii) a pro-rata share of the annual incentive bonus for the year in which the termination occurred, to be paid when and if such bonus would have been paid under the employment agreement; (iii) accelerated partial vesting of all unvested time-based equity awards with respect to the same number of shares that would have vested if Dr. Litchman had continued in employment for one year following the termination date; and (iv) if Dr. Litchman timely elects continued health insurance coverage under COBRA, the entire premium necessary to continue such coverage for Dr. Litchman and Dr. Litchman’s eligible dependents until the conclusion of the time when Dr. Litchman is receiving continuation of base salary payments or until Dr. Litchman becomes eligible for group health insurance coverage under another employer’s plan, whichever occurs first, provided however that we have the right to terminate such payment of COBRA premiums on behalf of Dr. Litchman and instead pay him a lump sum amount equal to the COBRA premium times the number of months remaining in the specified period if we determine in our discretion that continued payment of COBRA premiums is or may be discriminatory under Section 105(h) of the Internal Revenue Code. In addition, if Dr. Litchman is terminated without cause or resigns for good reason within twelve months following a change in control, he will be entitled to the severance benefits described in (i), (ii) and (iv) of the immediately preceding sentence, as well as 100% accelerated vesting of the options and other equity awards granted to him. In the event Dr. Litchman’s employment is terminated due to his death or disability, he or his estate will receive continuing salary payments for ninety days and a pro-rata share of the annual incentive bonus for the year in which the termination occurred, to be paid when and if such bonus would have been paid under the employment agreement. In each case, the severance benefits are conditioned upon Dr. Litchman’s execution and non-revocation of a release of claims against us and compliance with certain non-solicitation and non-competition covenants during his employment and for a period of six months thereafter. Also, the severance benefits are subject to reduction to avoid the imposition of excise taxes under Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended (the “IRC”), provided that such reduction would result in a better after-tax result for Dr. Litchman.

Annual Cash Incentive Bonus

In 2025, Dr. Litchman was eligible to earn a target annual cash incentive equal to 50% of his base salary per the terms of his Employment Agreement.

Dr. Litchman’s annual cash incentive bonus is based upon our performance against pre-established corporate goals and objectives, which included a combination of clinical and nonclinical goals related to our products as well as other corporate development goals, and his individual performance based upon subjective performance reviews. In 2025, the Compensation Committee decided not to pay the 2025 annual cash incentive bonus to preserve our limited cash resources.

Equity Awards

We maintain the Mustang Bio, Inc. 2016 Incentive Plan (the “EIP”), pursuant to which it may, from time to time, grant equity awards to its service providers, including its executive officers and directors. However, no equity awards were granted in 2025.

19

Table of Contents

Outstanding Equity Awards at Fiscal Year-End 2025

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Option Awards

​

Stock Awards

​

​

​

​

​

​

​

​

​

​

​

​

​

Market Value

​

​

Number of

​

Number of

​

​

​

​

​

​

Number of

​

of Shares or

​

​

securities

​

securities

​

​

​

​

​

​

Shares or

​

Units of Stock

​

​

underlying

​

underlying

​

Option

​

​

​

Units of

​

That Have

​

​

unexercised

​

unexercised

​

exercise

​

Option

​

Stock That

​

Not

​

​

options (#)

​

options (#)

​

price

​

Expiration

​

Have Not

​

Vested(1)

Name

  ​ ​ ​

exercisable

  ​ ​ ​

unexercisable

  ​ ​ ​

($)

  ​ ​ ​

Date

  ​ ​ ​

Vested (#)

  ​ ​ ​

($)

Manuel Litchman M.D.

 

868

​

520

(2)​

$

4,297.50

 

4/24/2027

 

71

(3)​

$

70

(1)Market value is based on $0.981 per share, the closing price of our common stock on the Nasdaq Capital Market on December 31, 2025, the last trading day of the fiscal year.
(2)The unvested portion of the option will vest and become exercisable upon the occurrence of the following milestones being achieved, in each case subject to Dr. Litchman’s continuous service to the Company on the date of such occurrences: (A) 25% of such shares will vest upon the dosing of the first patient in the first Phase 2 clinical trial of a second Company product candidate; (B) 25% of such shares will vest upon our achievement of a fully-diluted market capitalization of $500,000,000; and (C) 25% of such shares will vest upon our achievement of a fully-diluted market capitalization of $1 billion. Notwithstanding the foregoing, in the event that a Phase 2 clinical trial for the Company product candidates referenced in subsection (A) of this paragraph is bypassed, the corresponding percentage of the Performance Option grant that would have otherwise vested pursuant to subsection (A) of this paragraph will vest upon the earlier of (x) the dosing of the first patient in the first Phase 3 clinical trial for that Company product candidate, or (y) the filing of a Biologics License Application or New Drug Application with the U.S. Food and Drug Administration, or alternatively the filing of an equivalent regulatory filing with a foreign regulatory agency, with respect to that Company product candidate.
(3)These restricted stock units vest as follows: (i) 46 shares vested on April 24, 2026; and (ii) 25 shares will vest on April 24, 2027.

Policies and Practices for Granting Equity Awards

We do not have a formal written policy in place with regard to the timing of awards of options in relation to the disclosure by us of material nonpublic information, but the Board and the Compensation Committee do not take material non-public information into account when determining the timing or terms of stock options. The Board and Compensation Committee do not time the release of material nonpublic information for the purpose of affecting the value of executive compensation. During the fiscal year ended December 31, 2025, no equity awards were granted.

​

​

20

Table of Contents

PAY VERSUS PERFORMANCE

The following table shows, for the past three fiscal years, total compensation for our named executive officers as set forth in the Summary Compensation Table, the “compensation actually paid” to our named executive officers (as determined under SEC rules), the value of an initial $100 investment based on our total shareholder return (“TSR”), and our net income.

 

“Compensation actually paid” represents a compensation measure mandated by the SEC, the intent of which is to try to isolate the amount of compensation earned by an NEO in a given year. To calculate “compensation actually paid,” we are required to start with the total for that year reported in the Summary Compensation Table, deduct the Summary Compensation Table values for stock and option awards, and then add back amounts for new and previously outstanding stock and option awards in a manner mandated by the SEC. The calculations are complex, and the amounts determined in accordance with the rules often bear no relation to the money or the economic value received or realized by a particular NEO in the given year. We therefore caution that the term “compensation actually paid” should not be read literally and does not actually reflect the “take home” amounts received by an NEO in a given year.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Value of Initial

​

​

​

​

​

​

Summary

​

​

​

​

​

Average Summary

​

​

​

​

​

Fixed $100

​

​

​

​

​

​

Compensation Table

​

​

​

​

​

Compensation Table

​

​

Average

​

​

Investment Based

​

​

​

​

​

​

Total for Principal

​

​

Compensation

​

​

Total for Non-PEO

​

​

Compensation

​

​

on Total

​

​

Net Income

​

​

​

Executive Officer

​

​

Actually Paid to

​

​

Named Executive

​

​

Actually Paid to Non-

​

​

Shareholder

​

​

(Loss)

Year

​

​

("PEO")(1)

​

​

PEO(2)

​

​

Officers ("NEOs")(3)

​

​

PEO NEOs(3)

​

​

Return ("TSR")(4)

​

​

(thousands)(5)

2025

​

$

498,263

​

$

497,284

​

$

—

​

$

—

​

$

0.33

​

$

(1,921)

2024

​

​

498,042

​

​

487,213

​

​

199,485

​

​

199,485

​

​

2.99

​

​

(15,752)

2023

​

​

514,479

​

​

426,916

​

​

244,283

​

​

244,283

​

​

22.79

​

​

(51,602)

​

(1)Dr. Litchman was the Registrant’s PEO for each of the 2025, 2024 and 2023 fiscal years.

​

(2)The amounts disclosed reflect the adjustments listed in the table below to the amounts reported in the Summary Compensation Table for PEO:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Plus: Change in

​

​

Plus: Vesting Date

​

​

Plus: Year-Over-

​

​

Plus: Change in

​

​

​

​

​

​

​

​

​

Less: Grant Date

​

​

Value of Awards

​

​

Value of Awards

​

​

Year Change in

​

​

Value of Awards

​

​

​

​

​

​

​

​

​

Value of Equity

​

​

Granted During the

​

​

that Vested During

​

​

Fair Value of

​

​

Vested During the

​

​

Dividends on

​

​

Total

Year

​

​

Awards

​

​

Current Year

​

​

the Year

​

​

Unvested Awards

​

​

Current Year

​

​

Unvested Awards

​

​

Adjustments

2025

​

$

—

​

$

—

​

$

82

​

$

(559)

​

$

(502)

​

$

—

​

$

(979)

​

(3)For the 2025 fiscal year, we had no Non-PEO NEOs. For the 2024 fiscal year, our Non-PEO NEO was James Murphy, our former Interim Chief Financial Officer. For the 2023 fiscal year, our Non-PEO NEO was Eliot Lurier, our former Interim Chief Financial Officer.

​

(4)Represents the value as of the end of each year of a hypothetical $100 investment in the Company’s common stock on December 30, 2022, assuming dividend reinvestment.

​

(5)The dollar amounts reported represent the amount of net income (loss) reflected in our audited financial statements for the applicable year.

​

​

21

Table of Contents

Compensation Actually Paid and Net Income (Loss)

 

The following chart reflects the relationship between the amount of “compensation actually paid” to our PEO, the average “compensation actually paid” to our Non-PEO NEOs (if any), and our net income (loss) for the last three years. Due to the nature of our Company’s consolidated financials and primary focus on research and development of novel therapies, our Company has not historically utilized net income (loss) as a performance measure for our executive compensation program.

​

Graphic

​

​

22

Table of Contents

PEO and Non-PEO NEO Compensation Actually Paid and Company Total Shareholder Return

 

The following chart sets forth the relationship between “compensation actually paid” to our PEO, the average of “compensation actually paid” to our Non-PEO NEOs (if any), and the Company’s TSR over the last three years.

​

Graphic

​

All information provided above under the “Pay Versus Performance” heading will not be deemed to be incorporated by reference in any filing of our company under the Securities Act of 1933, as amended (the “Securities Act”), whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

​

​

23

Table of Contents

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS

The following table contains information about our equity compensation plans as of December 31, 2025.

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Equity Compensation Plan Information

​

​

 

​

​

​

​

​

​

​

Number of securities

 

​

​

​

​

​

​

​

remaining available

 

​

​

​

​

Weighted-

​

for future issuance

 

​

​

​

​

average

​

under equity

 

​

​

Number of securities to be

​

exercise price of

​

compensation plans

 

​

​

issued upon exercise of

​

outstanding

​

(excluding securities

 

​

​

outstanding options,

​

options, warrants

​

reflected in

 

Plan Category

​

warrants and rights

​

and rights (1)

​

column (a)) (2)

 

​

  ​ ​ ​

(a)

  ​ ​ ​

(b)

  ​ ​ ​

(c)

​

Equity compensation plans approved by security holders

 

1,617

​

$

4,297.50

 

2,756,958

(3)​

Equity compensation plans not approved by security holders

 

—

​

 

—

 

—

​

Total

 

1,617

​

$

4,297.50

 

2,756,958

(3)​

​

(1)The calculation of the weighted-average exercise price of outstanding options, warrants and rights does not include restricted stock units, as they do not have an exercise price.
(2)Our equity compensation plans consist of the EIP, and the Mustang Bio, Inc. 2019 Employee Stock Purchase Plan, which were each approved by our stockholders. We do not have any equity compensation plans or arrangements that have not been approved by our stockholders.
(3)Reflects 2,506,958 shares available for future issuance under the EIP and 250,000 shares available for future issuance under the ESPP.

DIRECTOR COMPENSATION

Director Compensation Program

In January 2016, the Board adopted a Non-Employee Directors Compensation Plan for our non-employee directors, which determines the cash and equity compensation payable to our non-employee directors. The Non-Employee Directors Compensation Plan provides for our non-employee directors to receive the following compensation:

Cash Compensation:

●$50,000 annual retainer; and

​

●$10,000 additional annual retainer for the Audit Committee Chair.

​

However, for Mr. Weiss, in lieu of the cash compensation described above, $60,000 of annual cash compensation is paid to the Advisor according to the Advisory Agreement

​

24

Table of Contents

Equity Compensation:

●Initial Equity Grant: 50,000 shares of restricted stock, which shares shall vest and become non-forfeitable in equal annual installments over three years, beginning on the third (3rd) anniversary of the grant date, subject to the director’s continued service on the Board on such date.

​

●Re-Election Equity Grant: The greater of (i) a number of shares of restricted stock having a fair market value on the grant date of $50,000, or (ii) 10,000 shares of restricted stock, which shares shall vest and become non-forfeitable on the third (3rd) anniversary of the grant date, subject to the director’s continued service on the Board on such date.

​

However, notwithstanding the Non-Employee Directors Compensation Plan, no stock awards were granted to our non-employee directors in 2025 because the grants have not yet been approved.

In addition, each non-employee director receives reimbursement for reasonable travel expenses incurred in attending meetings of our Board and meetings of committees of our Board.

Director Compensation Table

The following table sets forth the cash and other compensation we paid to the non-employee members of our Board for all services in all capacities during 2025.

​

​

​

​

​

​

​

​

​

​

​

​

  ​ ​ ​

Fees Earned or

  ​ ​ ​

Stock

  ​ ​ ​

​

​

​

​

Paid in Cash

​

Awards

​

Total

Name

​

($)(1)

​

($)(2)

​

($)

Michael S. Weiss(3)

​

$

60,000

​

$

—

​

$

60,000

Adam J. Chill

​

​

60,000

​

​

—

​

​

60,000

Neil Herskowitz

​

​

50,000

​

​

—

​

​

50,000

David Jin

​

​

50,000

​

​

—

​

​

50,000

Lindsay A. Rosenwald, M.D.

​

​

50,000

​

​

—

​

​

50,000

Michael J. Zelefsky, M.D.

​

​

50,000

​

​

—

​

​

50,000

(1)Represents the cash retainer for serving on our Board and committees thereof.
(2)As of December 31, 2025, each of Mr. Herskowitz, Dr. Rosenwald, Mr. Weiss, Mr. Chill and Dr. Zelefsky had 144 shares of unvested restricted stock pursuant to prior awards.
(3)Pursuant to the Advisory Agreement, the Advisor is paid an annual cash fee of $60,000, for the services of Mr. Weiss as Chairman of the Board and Executive Chairman (in lieu of any cash compensation under the Non-Employee Directors Compensation Plan and in addition to any annual equity incentive grants paid to members of the Board).

​

DELINQUENT SECTION 16(a) REPORTS

Section 16(a) of the Exchange Act requires our directors, certain officers, and beneficial owners of more than ten percent of our common stock to file reports with the SEC indicating their holdings of and transactions in our equity securities, and to provide copies of such reports to us. Based solely on a review of our records, publicly available information, and written representations by the persons required to file such reports, we believe that during the fiscal year ended December 31, 2025, there were no delinquent Section 16(a) filings.

​

​

​

25

Table of Contents

RELATED-PERSON TRANSACTIONS

Except as set forth below, since January 1, 2024, we have not been a party to any transaction in which the amount involved exceeded or will exceed the lesser of $120,000 or one percent (1%) of the average of our total assets at year-end for the last two completed fiscal years, and in which any of our directors, NEOs, or beneficial owners of more than 5% of our capital stock, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest, and other than compensation, termination, and change-in-control arrangements.

The written charter of the Audit Committee authorizes, and Nasdaq rules require, the Audit Committee to review and approve related-party transactions. In reviewing related-party transactions, the Audit Committee applies the basic standard that transactions with affiliates should be made on terms no less favorable to us than could have been obtained from unaffiliated parties. Therefore, the Audit Committee reviews the benefits of the transactions, terms of the transactions and the terms available from unrelated third parties, as applicable. All transactions other than compensatory arrangements between us and our officers, directors, principal stockholders and their affiliates will be approved by the Audit Committee or a majority of the disinterested directors and will continue to be on terms no less favorable to us than could be obtained from unaffiliated third parties.

The following is a summary of each transaction or series of similar transactions since January 1, 2024, to which we were or are a party and that:

●the amount involved exceeded or exceeds the lesser of $120,000 or one percent (1%) of the average of our total assets at year-end for the last two completed fiscal years; and

​

●any of our directors or executive officers, any holder of 5% of our capital stock or any member of their immediate family had or will have a direct or indirect material interest.

​

Founders Agreement and Management Services Agreement with Fortress

Effective March 13, 2015, we entered into a Founders Agreement with Fortress, which was amended and restated on May 17, 2016, and again on July 26, 2016 (the “Mustang Founders Agreement”). The Mustang Founders Agreement provides that, in exchange for the time and capital expended in the formation of our company and the identification of specific assets, the acquisition of which result in the formation of a viable emerging growth life science company, Fortress loaned $2.0 million, representing the up-front fee required to acquire our license agreement with COH. The Mustang Founders Agreement has a term of 15 years, which upon expiration automatically renews for successive one-year periods unless terminated by Fortress and the Company or a Change in Control (as defined in the Mustang Founders Agreement) occurs. Concurrently with the second amendment on July 26, 2016, to the Mustang Founders Agreement, Fortress entered into an Exchange Agreement whereby Fortress exchanged its 7.25 million Class B Common shares for 9,333 common shares and 250,000 Class A Preferred shares. Class A Preferred Stock is identical to common stock other than as to voting rights, conversion rights and the Annual Stock Dividend right (as described below). Each share of Class A Preferred Stock is entitled to vote the number of votes that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the shares of our outstanding common stock and (B) the whole shares of our common stock into which the shares of outstanding Class A common stock and Class A Preferred Stock are convertible and the denominator of which is the number of shares of outstanding Class A Preferred Stock. Thus, the Class A Preferred Stock will at all times constitute a voting majority. Each share of Class A Preferred Stock is convertible, at Fortress’ option, into one fully paid and nonassessable share of our common stock, subject to certain adjustments. As holders of Class A Preferred Stock, Fortress will receive on each January 1 (each a “Annual Stock Dividend Payment Date”) until the date all outstanding Class A Preferred Stock is converted into common stock, pro rata per share dividends paid in additional fully paid and nonassessable shares of common stock (“Annual Stock Dividends”) such that the aggregate number of shares of common stock issued pursuant to such Annual Stock Dividend is equal to two and one-half percent (2.5%) of our fully-diluted outstanding capitalization on the date that is one (1) business day prior to any Annual Stock Dividend Payment Date.

​

26

Table of Contents

As additional consideration under the Mustang Founders Agreement, we are required to: (i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing that occurs after the effective date of the Mustang Founders Agreement and ending on the date when Fortress no longer has majority voting control in our voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of our annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, we will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%).

Effective as of March 13, 2015, we entered into a Management Services Agreement (the “MSA”) with Fortress, pursuant to which Fortress renders advisory and consulting services to us. The MSA has an initial term of five years and is automatically renewed for successive five-year terms unless terminated in accordance with its provisions. Services provided under the MSA may include, without limitation, (i) advice and assistance concerning any and all aspects of our operations, clinical trials, financial planning and strategic transactions and financings and (ii) conducting relations on our behalf with accountants, attorneys, financial advisors and other professionals (collectively, the “Services”). We are obligated to utilize clinical research services, medical education, communication and marketing services and investor relations/public relation services of companies or individuals designated by Fortress, provided those services are offered at market prices.

However, we are not obligated to take or act upon any advice rendered from Fortress and Fortress shall not be liable for any of its actions or inactions based upon their advice. Pursuant to the MSA and our Certificate of Incorporation, Fortress and its affiliates, including all members of our Board, will have no fiduciary or other duty to communicate or present any corporate opportunities to us or to refrain from engaging in business that is similar to that of our company. In consideration for the Services, we pay Fortress an annual consulting fee of $0.5 million (the “Annual Consulting Fee”), payable in advance in equal quarterly installments on the first business day of each calendar quarter in each year, provided, however, that such Annual Consulting Fee shall be increased to $1.0 million for each calendar year in which we have net assets in excess of $100 million at the beginning of the calendar year. We record fifty percent of the Annual Consulting Fee in research and development expense and fifty percent in general and administrative expense in the Statement of Operations. For the years ended December 31, 2025 and 2024, we recorded expense of $0.5 million and $0.5 million, respectively, related to this agreement.

For the year ended December 31, 2025, the Company issued 127,140 shares of common stock to Fortress, which equaled 2.5% of the sum of the gross proceeds of $0.6 million from the sale of shares of common stock under Mustang’s At-the-Market Offering, $8.0 million gross proceeds from the February 2025 Equity Offering, and $7.1 million from the July 2025 Series C-2 warrant exercises. The Company recorded an expense of approximately $0.4 million in general and administrative expenses related to these shares for the year ended December 31, 2025.

For the year ended December 31, 2024, we issued 23,450 shares of common stock to Fortress, which equaled 2.5% of the gross proceeds of $2.6 million from the sale of shares of common stock under our At-the-Market Offering and $4.0 million gross proceeds from the May 2024 Public Offering, $2.5 million from the June 2024 PIPE, and $4.0 million from the October 2024 warrant exercise. We recorded expense of approximately $0.3 million in general and administrative expenses related to these shares for the year ended December 31, 2024.

In addition, pursuant to our Certificate of Incorporation, on January 1, 2026, we issued 278,385 shares of common stock to Fortress as the Annual Stock Dividend, representing 2.5% of our fully-diluted outstanding equity, and recorded an expense of approximately $0.3 million in research and development expense during the year ended December 31, 2025 related to these shares. On January 1, 2025, we issued 69,046 shares of common stock to Fortress as the Annual Stock Dividend and recorded an expense of approximately $0.6 million in research and development expense during the year ended December 31, 2024 related to these shares.

Payables and Accrued Expenses Related Party

In the normal course of business, Fortress pays for certain expenses on our behalf. Such expenses are recorded as Payables and accrued expenses - related party.

27

Table of Contents

Director Compensation

Dr. Rosenwald and Mr. Jin

Pursuant to the terms of our Non-Employee Directors Compensation Plan, Dr. Rosenwald and Mr. Jin will receive a cash fee of $50,000 per year paid quarterly and an annual stock award of the greater of (i) a number of shares of common stock having a fair market value on the grant date of $50,000 or (ii) 10,000 shares of common stock, which shares shall vest and become non-forfeitable on the third anniversary of the grant date, subject to their continued service on the Board on such date. Dr. Rosenwald is Chairman, President and Chief Executive Officer of Fortress and Mr. Jin is Chief Financial Officer and Head of Corporate Development of Fortress. We are a controlled subsidiary of Fortress.

For the year ended December 31, 2025, we recognized $50,000 and $50,000 for Dr. Rosenwald and Mr. Jin, respectively, in expense related to the director compensation. For the year ended December 31, 2024, we recognized $50,000 and $12,500 for Dr. Rosenwald and Mr. Jin, respectively, in expense in our Statements of Operations related to the director compensation. No restricted stock awards were granted in 2025 and 2024.

Mr. Weiss - Advisory Agreement with Caribe BioAdvisors, LLC

The Board approved and authorized our entrance into an advisory agreement, dated January 1, 2017 (the “Advisory Agreement”), with Caribe BioAdvisors, LLC (the “Advisor”), owned by Michael S. Weiss, the Chairman of the Board, to provide the board advisory services of Mr. Weiss as Chairman of the Board. Pursuant to the Advisory Agreement, the Advisor will be paid an annual cash fee of $60,000, paid quarterly and an annual stock award of the greater of (i) a number of shares of common stock having a fair market value on the grant date of $50,000 or (ii) 10,000 shares of common stock, which shares shall vest and become non-forfeitable on the third anniversary of the grant date, subject to continued service on the Board on such date.

For the year ended December 31, 2025, we recognized $60,000 in expense related to the Advisory Agreement. For the year ended December 31, 2024, we recognized $60,000 in expense in our Statements of Operations related to the Advisory Agreement. No restricted stock awards were granted in 2025 and 2024.

​

28

Table of Contents

STOCK OWNERSHIP OF OUR DIRECTORS, EXECUTIVE OFFICERS, AND 5% BENEFICIAL OWNERS

The following table shows information, as of November 17, 2026, concerning the beneficial ownership of our common stock by:

●each person we know to be the beneficial owner of more than 5% of our common stock;

​

●each of our current directors;

​

●each of our NEOs shown in our Summary Compensation Table; and

​

●all current directors and NEOs as a group.

​

As of November 17, 2026, there were 6,738,693 shares of our common stock, 845,385 shares of our Class A common stock, and 250,000 shares of our Class A Preferred Stock outstanding. In order to calculate a stockholder’s percentage of beneficial ownership, we include in the calculation those shares underlying options or warrants beneficially owned by that stockholder that are vested or that will vest within 60 days of November 17, 2026. Shares of restricted stock are deemed to be outstanding. Options or warrants held by other stockholders that are not attributed to the named beneficial owner are disregarded in this calculation. Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the shares of our common stock. Unless we have indicated otherwise, each person named in the table below has sole voting power and investment power for the shares listed opposite such person’s name, except to the extent authority is shared by spouses under community property laws.

​

​

​

​

​

​

​

​

​

​

​

Shares Under

​

​

 

​

​

​

Exercisable

​

​

 

​

​

​

Options and

​

​

 

​

​

​

Unvested

Total Shares

​

 

​

​

​

Restricted Stock

Beneficially

% of Total

​

Name of Beneficial Owner(1)

  ​ ​ ​

Shares Owned

Units (2)

Owned

Common Stock

 

Michael S. Weiss (3)

​

991

—

991

*

%

Manuel Litchman, M.D

 

1,590

868

2,458

*

%

Lindsay A. Rosenwald, M.D (3)

 

1,008

—

1,008

*

%

Neil Herskowitz

 

145

—

145

*

%

David Jin

​

286

—

286

*

%

Adam J. Chill

 

375

—

375

*

%

Michael J. Zelefsky, M.D

 

379

—

379

*

%

All current executive officers and directors as a group (7 persons)

 

4,774

868

5,642

*

%

5% or Greater Stockholders:

 

  ​

  ​

​

​

​

Fortress Biotech, Inc. (4)

 

536,577

—

536,577

8.0

%

*

Less than 1% of our common stock outstanding

(1)The address of each of the directors and executive officers is c/o Mustang Bio, Inc., 95 Sawyer Road, Suite 110, Waltham, Massachusetts 02453, and the address of Fortress Biotech, Inc. is c/o Fortress Biotech, Inc., 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154.
(2)Includes only options exercisable within 60 days of November 17, 2026 and restricted stock units vesting within 60 days of November 17, 2026.

29

Table of Contents

(3)Includes 666 warrants issued by Fortress to each of Mr. Weiss and Dr. Rosenwald that cover shares of our common stock that are owned by Fortress. These do not represent equity compensation by us to either Mr. Weiss or Dr. Rosenwald.
(4)Includes shares underlying 666 warrants issued to each of Mr. Weiss and Dr. Rosenwald, and excludes 250,000 of Class A Preferred Stock, which are convertible into 333 shares of Common Stock.

The following table shows information, as of November 17, 2026, concerning the beneficial ownership of our Class A Common Stock:

​

​

​

​

​

​

​

​

​

Class A Common Stock

 

​

​

Beneficially Owned

 

​

  ​ ​ ​

Number of

  ​ ​ ​

​

 

​

​

Shares and

​

​

 

​

​

Nature of

​

Percentage of

 

​

​

Beneficial

​

Total Class A

 

Name and Address of Beneficial Owner(1)

​

Ownership(2)

​

Common Stock

 

City of Hope

 

845,385

 

100

%

(1)The address City of Hope is 1500 East Duarte Road, Duarte, California 91010.
(2)Converts into 1,127 shares of common stock.

​

The following table shows information, as of November 17, 2026, concerning the beneficial ownership of our Class A Preferred Stock:

​

​

​

​

​

​

​

​

​

Class A Preferred Stock

 

​

​

Beneficially Owned

 

​

  ​ ​ ​

Number of

  ​ ​ ​

​

 

​

​

Shares and

​

​

 

​

​

Nature of

​

Percentage of

 

​

​

Beneficial

​

Total Class A

 

Name and Address of Beneficial Owner(1)

​

Ownership(2)

​

Preferred Stock

 

Fortress Biotech, Inc.

 

250,000

 

100

%

(1)The address of Fortress Biotech, Inc. is c/o Fortress Biotech, Inc., 1111 Kane Concourse Suite 301 Bay Harbor Islands, FL 33154.
(2)Converts into 333 shares of common stock.

​

30

Table of Contents

PROPOSAL ONE: ELECTION OF DIRECTORS; NOMINEES

Our Bylaws provide that the Board shall consist of not more than nine nor less than one member, as determined from time to time by resolution of the Board. Our Board currently consists of seven members. The nominated directors are: Manuel Litchman, M.D., Michael S. Weiss, Adam J. Chill, Neil Herskowitz, David Jin, Lindsay A. Rosenwald, M.D., and Michael J. Zelefsky, M.D. For information about each of the nominees and our Board generally, please see “Corporate Governance - Current Directors/Nominees” beginning on page 9. If elected, the nominees will hold office until the next annual meeting and until a respective successor is elected and has been qualified, or until such director resigns or is removed from office. Management expects that each of the nominees will be available for election, but if any of them is unable to serve at the time the election occurs, your proxy will be voted for the election of another nominee to be designated by a majority of the independent directors serving on our Board.

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE ELECTION OF ALL OF THE NOMINEES FOR DIRECTOR. IF A CHOICE IS SPECIFIED ON THE PROXY BY THE STOCKHOLDER, THE SHARES WILL BE VOTED AS SPECIFIED. IF NO SPECIFICATION IS MADE, THE SHARES WILL BE VOTED “FOR” ALL OF THE NOMINEES. THE AFFIRMATIVE VOTE OF A PLURALITY OF THE VOTES CAST BY THE HOLDERS OF SHARES PRESENT OR REPRESENTED BY PROXY AND ENTITLED TO VOTE AT THE ANNUAL MEETING IS REQUIRED FOR THE ELECTION OF THE NOMINEES.

​

​

31

Table of Contents

PROPOSAL TWO: RATIFICATION OF APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board is submitting the selection of KPMG LLP as our independent registered public accounting firm to the stockholders for ratification at our Annual Meeting. Stockholder ratification of our independent registered public accounting firm is not required by our Bylaws or otherwise. If KPMG LLP is not ratified as our independent registered public accounting firm by a majority of the votes of the shares present or represented by proxy, the Board will review its future selection of its independent registered public accounting firm. KPMG LLP will still serve as our independent registered public accounting firm for the year ending December 31, 2026, if it is not ratified by our stockholders.

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS THE COMPANY’S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2026. THE AFFIRMATIVE VOTE OF A MAJORITY OF VOTES OF THE SHARES PRESENT VIRTUALLY OR REPRESENTED BY PROXY AT THE MEETING AND ENTITLED TO VOTE ON THE SUBJECT MATTER IS REQUIRED FOR APPROVAL.

​

​

32

Table of Contents

PROPOSAL THREE: ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS

We are asking our stockholders to vote to approve, on an advisory basis, the compensation of our named executive officer as disclosed in this proxy statement, including the section titled “Executive Compensation,” and any related material as required pursuant to Section 14A of the Exchange Act. This proposal, commonly known as a “Say-On-Pay” proposal, gives our stockholders the opportunity to express their views on our named executive officer’s compensation. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officer and the compensation philosophy, policies and practices described in this proxy statement.

At our 2023 Annual Meeting of Stockholders, the last time the stockholders were asked to approve the compensation of our named executive officers, the stockholders approved, on an advisory basis, the compensation of our named executive officers. At that meeting, the stockholders also voted, on an advisory basis, on the frequency of future Say-On-Pay votes and recommended holding them every three years. Consistent with that recommendation and our Board’s recommendation, we hold a Say-On-Pay vote every three years. An advisory vote on the frequency of the Say-On-Pay vote is required every six years. Accordingly, unless the Board determines otherwise (or proposed SEC rules exempting certain issuers from such votes are finalized and applicable to us), we expect our next Say-On-Pay vote and our next advisory vote on the frequency of Say-On-Pay votes to be held at our 2029 Annual Meeting of Stockholders.

This vote is advisory, and therefore not binding on the Company or our Board. Our Board values the opinions of the stockholders and to the extent there is any significant vote against the named executive officer compensation as disclosed in this proxy statement, we will consider our stockholders’ concerns and the Board will evaluate whether any actions are necessary to address those concerns.

We believe that the policies and procedures articulated in the “Executive Compensation” section of this proxy statement are effective in achieving the Company’s goals and that the executive compensation reported in this proxy statement was appropriate and aligned with 2025 fiscal year results. Before voting, we encourage our stockholders to read the “Executive Compensation” section of this proxy statement for additional details about our executive compensation programs and named executive officer compensation in fiscal year 2025. We are asking stockholders to indicate their support for our named executive officer compensation as described in this proxy statement.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE RESOLUTION APPROVING THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICER, AS FOLLOWS:

RESOLVED, that the compensation paid to the Company’s named executive officer, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion, is hereby approved.

THE AFFIRMATIVE VOTE OF A MAJORITY OF VOTES OF THE SHARES PRESENT VIRTUALLY OR REPRESENTED BY PROXY AT THE MEETING AND ENTITLED TO VOTE ON THE SUBJECT MATTER IS REQUIRED FOR APPROVAL.

​

​

​

​

​

33

Table of Contents

PROPOSAL FOUR: APPROVAL OF THE REVERSE SPLIT AMENDMENT AND AUTHORIZATION OF THE BOARD TO DETERMINE THE RATIO AND EFFECT THE REVERSE STOCK SPLIT

The Board is submitting to the stockholders for approval the Reverse Split Amendment, an amendment to the Company’s Certificate of Incorporation to effect the Reverse Stock Split of the Company’s issued and outstanding common stock at a ratio of between 1-for-5 and 1-for-30, with the Ratio to be determined at the sole discretion of the Board and with such Reverse Stock Split to be effected at such time and date before December 21, 2027, if at all, as determined by the Board in its sole discretion. Notwithstanding the foregoing, the Board will not select a Ratio that it reasonably believes, at the time of selection, would cause the Company to fail to satisfy any other applicable continued listing requirement of Nasdaq, including the minimum number of publicly held shares.  If approved, and deemed necessary by the Board, the Reverse Split Amendment will be effective upon the filing of a certificate of amendment to our Certificate of Incorporation, or at such other date and time as may be specified in the Reverse Split Amendment, in substantially the form attached to this proxy statement as Appendix A, with the Secretary of State of the State of Delaware, with the timing of such filing to occur, if at all, at the sole discretion of the Board.

Each share of common stock entitles the holder thereof to one non-cumulative vote for each share held of record on all matters submitted to a vote of the stockholders and to participate equally and to receive any and all such dividends as may be declared by the Board, subject to the payment of all dividends on the Class A Preferred Stock.  Holders of our common stock have no preemptive rights to acquire additional shares of common stock or any other securities.  The common stock is not subject to redemption and carries no subscription or conversion rights.

If the Reverse Split Amendment is approved by our stockholders, the Board will have the authority, in its sole discretion, without further action by our stockholders, to effect the Reverse Split Amendment. Even if our stockholders approve the Reverse Split Amendment, the Board reserves the right not to effect the Reverse Stock Split if it does not deem it to be in the best interests of our stockholders. Upon implementation of the Reverse Split Amendment, up to 30 shares of outstanding common stock will be automatically converted into one share of common stock.

Purposes of the Reverse Split Amendment

We are submitting this proposal to our stockholders for approval in order to try and increase the trading price of our common stock to help ensure a share price high enough to satisfy the Bid Price Requirement for continued listing on the Nasdaq Capital Market. For our common stock to continue trading on the Nasdaq Capital Market, we must comply with various listing standards, including maintaining a minimum closing bid price of $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2).

On April 15, 2026, we received written notification (the “Notice Letter”) from Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that we were not in compliance with Nasdaq Listing Rule 5550(a)(2), as the closing bid price for our common stock was below the $1.00 per share requirement for the previous 30 consecutive business days. The Notice Letter stated that we had 180 calendar days, or until October 12, 2026, to regain compliance with the Bid Price Requirement. On October 13, 2026, we were granted an additional 180 calendar days, or until April 12, 2027, to regain compliance with the Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we will regain compliance by evidencing a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days (but generally not more than 20 consecutive business days). We believe that the Reverse Stock Split is our best means of increasing and maintaining the price of our common stock to above $1.00 per share in compliance with Nasdaq requirements.

The Board would effect the Reverse Stock Split only upon its determination that the Reverse Stock Split would be in our and our stockholders’ best interests following stockholder approval. If our Board were to effect the Reverse Stock Split, our Board would determine the Ratio (which will be with an exchange ratio between five-for-one and thirty-for-one), set the timing for the Reverse Stock Split and file the Reverse Split Amendment. No further action on the part of stockholders is required to either implement or abandon the Reverse Stock Split. If our Board determines to implement the Reverse Stock Split, we will publicly announce, prior to the effective date of the Reverse Stock Split (the “Effective Date”), additional details regarding the Reverse Stock Split. The Board reserves its right to elect not to proceed, and to abandon, the Reverse Stock Split if it determines, in its sole discretion, that this proposal is no longer in our best interests.

34

Table of Contents

 

We cannot assure you that the Reverse Stock Split will have any of the desired effects described above. More specifically, we cannot assure you that after the Reverse Stock Split the market price of our common stock will increase proportionately to reflect the ratio for the Reverse Stock Split, that the market price of our common stock will not decrease to its pre-split level, or that our market capitalization will be equal to the market capitalization before the Reverse Stock Split.

Potential Risks of the Reverse Split Amendment

Although the principal purpose of the Reverse Stock Split would be to help increase the per-share market price of our common stock, there can be no assurance that the Reverse Stock Split will result in any particular price for our common stock.  If the Reverse Stock Split is effected and the market price of our common stock declines, the percentage decline may be greater than would occur in the absence of a Reverse Stock Split.  As a result, the trading liquidity of our common stock may not necessarily improve. Additionally, there can be no assurance that the market price per share of our common stock after the Reverse Stock Split will increase in proportion to the reduction in the number of shares of our common stock outstanding before the Reverse Stock Split.  For example, based on the closing price of $0.3909 per share of our common stock on November 17, 2026, if the Reverse Stock Split were implemented at a ratio of 1-for-30, there can be no assurance that the post-split market price of our common stock would be $11.73 or greater.  Accordingly, the total market capitalization of our common stock after the Reverse Stock Split may be lower than the total market capitalization before the Reverse Stock Split.  Moreover, in the future, the market price of our common stock following the Reverse Stock Split may not exceed or remain higher than the market price prior to the Reverse Stock Split.

In addition, under Nasdaq Listing Rule 5810(c)(3)(A), the Company will not be considered to have regained compliance with the Bid Price Requirement if the Reverse Stock Split results in the Company’s common stock falling below the numeric threshold for another listing requirement without regard to any compliance periods otherwise available for that other listing requirement. Further, if the Company’s common stock fails to meet the Bid Price Requirement and the Company has effected a reverse stock split over the prior one-year period; or has effected one or more reverse stock splits (including our 1-for-50 reverse stock split effected on January 15, 2025) over the prior two-year period with a cumulative ratio of 250 shares or more to one, then the Company shall not be eligible for any compliance period and the Staff shall issue a delisting determination under Nasdaq Listing Rule 5810, subject to our right to request a hearing before a Nasdaq Hearings Panel.

The number of shares held by each individual holder of common stock would be reduced if the Reverse Stock Split is implemented. This may increase the number of stockholders who hold less than a “round lot” (i.e., 100 shares). Odd lot shares may be more difficult to sell, and brokerage commissions and other costs of transactions in odd lots are generally somewhat higher than the costs of transactions in “round lots” of even multiples of 100 shares. Consequently, the Reverse Stock Split could increase the transaction costs to existing holders of common stock in the event they wish to sell all or a portion of their position.

Additionally, the liquidity of our common stock could be affected adversely by the reduced number of shares outstanding after the Reverse Stock Split. Although our Board believes that a higher stock price may help generate investor interest, there can be no assurance that the Reverse Stock Split will result in a per share price that will attract institutional investors or investment funds or that such share price will satisfy the investing guidelines of institutional investors or investment funds. As a result, the decreased liquidity that may result from having fewer shares outstanding may not be offset by increased investor interest in our common stock. The market price of our common stock will also be based on our performance and other factors, some of which are unrelated to the number of shares outstanding.

The Board intends to effect the Reverse Stock Split only if it believes that a decrease in the number of shares is likely to improve the trading price of our common stock and if the implementation of the Reverse Stock Split is determined by the Board to be in the best interests of the Company and its stockholders. If neither of these conditions is present, then the Board will not proceed with the Reverse Stock Split.

​

35

Table of Contents

Potential Consequences if the Reverse Stock Split is Not Approved

If the Reverse Stock Split is not approved by our stockholders, our Board will not have the authority to effect the Reverse Split Amendment to, among other things, facilitate the continued listing of our common stock on Nasdaq by increasing the per share trading price of our common stock to help ensure a share price high enough to satisfy the Bid Price Requirement. Any inability of our Board to effect the Reverse Stock Split could expose us to delisting by Nasdaq.

Effecting the Reverse Stock Split

​

Upon receipt of stockholder approval for the Reverse Split Amendment, if our Board concludes that it is in the best interests of our Company and our stockholders to effect the Reverse Stock Split, the Reverse Split Amendment will be filed with the Secretary of State of the State of Delaware. The actual timing of the filing of the Reverse Split Amendment with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, will be determined by our Board. In addition, if for any reason our Board deems it advisable to do so, the Reverse Stock Split may be abandoned at any time prior to the filing of the Reverse Split Amendment, without further action by our stockholders. The Reverse Split Amendment will be effective as of the date of filing with the Secretary of State of the State of Delaware or at such other date and time as is specified in the Reverse Split Amendment (the “Effective Time”). 

Except as explained below with respect to fractional shares (see “—Principal Effects of the Reverse Stock Split – Treatment of Fractional Shares”), at the Effective Time, all shares of our common stock issued and outstanding immediately prior to the Effective Time will be combined, automatically and without any action on the part of stockholders, into a lesser number of shares of our common stock calculated in accordance with the Ratio determined by the Board. After the Effective Time, our common stock will have a new committee on uniform securities identification procedures (“CUSIP”) number, which is a number used to identify the Company’s equity securities, and stock certificates with the older CUSIP number will need to be exchanged for stock certificates with the new CUSIP number by following the procedures described below.

Principal Effects of the Reverse Stock Split

Common Stock

After the Effective Date of any Reverse Stock Split, each stockholder will own fewer shares of our common stock. Split shares issued in connection with the Reverse Stock Split will be fully paid and non-assessable. The number of stockholders is expected to remain unchanged as a result of the Reverse Stock Split. The Reverse Stock Split will decrease the number of outstanding shares of our common stock, but will not affect any stockholder’s proportionate interest in our Company, except for possible differences resulting from the treatment of any fractional shares as a result of the Reverse Stock Split. The par value of our common stock will remain unchanged.  While the aggregate par value of our outstanding common stock will be decreased, our additional paid-in capital will be increased by a corresponding amount. Therefore, the Reverse Stock Split will not affect our total stockholders’ equity.  All share and per share information included in our financial statements will be retroactively adjusted to reflect the Reverse Stock Split for all periods presented in our future financial reports and regulatory filings.

The Reverse Stock Split is likely to result in some stockholders owning “odd−lots” of fewer than 100 shares of common stock. Brokerage commissions and other costs of transactions in odd lots are generally somewhat higher than the costs of transactions on “round−lots” of even multiples of 100 shares.

There will be no change to the authorized capital of the Company as a result of the Reverse Stock Split. The number of authorized shares of common stock will remain 200,000,000, effectively increasing the number of authorized and unissued shares of our common stock available for future issuance. The Company will retain the corporate authority to issue in the future up to all such additional remaining shares of authorized but unissued common stock.  These shares may be issued without stockholder approval, subject to compliance with applicable Nasdaq rules, at any time in the sole discretion of our Board. The authorized and unissued shares may be issued for cash, to acquire property or for any other purpose that is deemed in the best interests of our Company.  Any decision to issue additional shares will reduce the percentage of our stockholders’ equity held by our current stockholders and could dilute our net tangible book value.

36

Table of Contents

Our authorized and unissued shares could possibly be used by management to oppose a hostile takeover attempt, delay or prevent changes of control, or changes in or removal of management.  This could include transactions that are favored by a majority of stockholders, or in which the stockholders might otherwise receive a premium for their shares over then-current market price or benefit stockholders in some other manner.  Tender offers or other non-open market acquisitions of stock are usually made at prices above the prevailing market price.  In addition, acquisitions of stock by persons attempting to acquire control through market purchases may cause the market price of the stock to reach levels that are higher than would otherwise be the case.

The available authorized and unissued shares of common stock give the Company the ability to cause a potential anti-takeover effect by creating potential dilution to the number of outstanding shares. Such dilution will cause a party attempting a takeover to be required to buy more shares of the Company stock and to expend additional resources to accomplish a takeover.  The Reverse Stock Split is not part of a plan by management to affect the ability of third parties to take over or change control of the Company, nor are we currently contemplating any such anti-takeover plan.

We will not become a private company as a result of the Reverse Stock Split, we expect that our common stock will continue to be quoted on the Nasdaq Capital Market as a fully reporting company immediately following the Reverse Stock Split, and we plan to continue to file periodic and other reports with the SEC under the Exchange Act.

Our common stock is currently registered under Section 12 of the Exchange Act, and we are subject to the periodic reporting requirements of the Exchange Act. The Reverse Stock Split would not affect the registration of our common stock under the Exchange Act in any material way.

Options, Warrants, Restricted Stock Units, Class A Common Stock and the Class A Preferred Stock

In addition, all outstanding options and warrants to purchase shares of our common stock and conversion rights under the Class A Common Stock and Class A Preferred Stock would be adjusted as a result of the Reverse Stock Split, as required by the terms of those securities. Restricted Stock Units will also be adjusted to reflect the Reverse Stock Split. In particular, the number of shares issuable upon the exercise or vesting of each instrument would be reduced, and the exercise price per share, if applicable, would be increased, in accordance with the terms of each instrument and based on the Ratio. The number of shares reserved for issuance under our existing stock option and equity incentive plans would be reduced proportionally based on the Ratio.

The Certificate of Incorporation provides for the automatic adjustment of the conversion ratio of our Class A Common Stock and Class A Preferred Stock in the event of a reverse stock split of our common stock. Pursuant to this automatic adjustment provision, the applicable conversion ratio in effect immediately before the Reverse Stock Split shall be proportionately increased so that the number of shares of common stock issuable on conversion of each share of Class A Common Stock or Class A Preferred Stock, as applicable, shall be decreased in proportion to the decrease in the aggregate number of outstanding shares of our common stock. As a result, the Class A Common Stock and Class A Preferred Stock will have all of the same rights and privileges on a proportionate basis vis-à-vis the other classes of the Company’s capital stock, as immediately prior to the effective time of the Reverse Stock Split.

When the Reverse Stock Split is implemented, the rights and preferences of the outstanding shares of the common stock will remain the same after the Reverse Stock Split. Each share of common stock issued pursuant to the Reverse Stock Split will be fully paid and non-assessable.

Treatment of Fractional Shares

We will not issue fractional shares of common stock in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive fractional shares because they hold a number of shares of common stock that is not evenly divided by the Ratio, will be entitled to receive a cash payment, without interest or deduction, rounded to the nearest cent, in an amount equal to the product obtained by multiplying (a) the closing price per share of our common stock as reported on the Nasdaq Capital Market as of the date of the Effective Time of the Reverse Stock Split, by (b) the fraction of one share owned by the stockholder.

37

Table of Contents

Effect on Non-Registered Stockholders

Non-registered stockholders holding our common stock through a bank, broker or other nominee should note that such banks, brokers or other nominees may have different procedures for processing the consolidation than those that would be put in place by us for registered stockholders. If you hold your shares with such a bank, broker or other nominee and if you have questions in this regard, you are encouraged to contact your nominee.

Book-Entry Shares

The combination of and reduction in the number of our outstanding shares of common stock as a result of the Reverse Stock Split would occur automatically on the Effective Date without any action on the part of our stockholders. Our registered stockholders may hold some or all of their shares electronically in book-entry form. These stockholders will not have stock certificates evidencing their ownership of common stock. They are, however, provided with a statement reflecting the number of shares of our common stock registered in their accounts.

Stockholders who hold registered shares of our common stock in book-entry form do not need to take any action to receive post-Reverse Stock Split shares of our common stock in registered book-entry form. These stockholders will have their pre-Reverse Stock Split shares exchanged automatically and a statement will be mailed to them upon exchange indicating the number of shares owned by such stockholders following the Reverse Stock Split.

Exchange of Stock Certificates

As soon as practicable after the Effective Date, transmittal forms will be mailed to each holder of record of certificates for shares of our common stock to be used in forwarding such certificates for surrender in exchange for, if so elected by the holder, new certificates representing the number of shares of our common stock held by such stockholder following the Reverse Stock Split. Our transfer agent will act as exchange agent for purposes of exchanging stock certificates. The transmittal forms will be accompanied by instructions specifying other details of the exchange. Upon receipt of the transmittal form, each stockholder should surrender the certificates representing shares of our common stock prior to the Reverse Stock Split in accordance with the applicable instructions. No new certificates will be issued to a stockholder until the stockholder has surrendered his or her outstanding stock certificate(s) together with the properly completed and executed transmittal form to the exchange agent.

STOCKHOLDERS SHOULD NOT DESTROY ANY STOCK CERTIFICATE(S) AND SHOULD NOT SUBMIT ANY STOCK CERTIFICATE(S) UNTIL REQUESTED TO DO SO.

Interests of Directors and Executive Officers

Our directors and executive officers have no substantial interest, direct or indirect, in the matters set forth in this Proposal Four, except to the extent of their ownership of shares of our common stock. We do not believe that our officers or directors have interests in Proposal Four that are different from or greater than those of any other of our stockholders.

No Appraisal Rights

Under the DGCL, stockholders are not entitled to appraisal rights with respect to the Reverse Stock Split, and we do not intend to independently provide stockholders with any such right.

Accounting Consequences

The par value per share of our common stock would remain unchanged at $0.0001 per share after the Reverse Stock Split. As a result, on the Effective Date of the Reverse Stock Split, the stated capital on our balance sheet attributable to our common stock would be reduced proportionally, based on the Ratio, from its present amount, and the additional paid-in capital account would be credited with the amount by which the stated capital is reduced. The loss per share and net book value per share would be increased because there would be fewer shares of our common stock outstanding. We do not anticipate that any other accounting consequences would arise as a result of the Reverse Stock Split.

38

Table of Contents

United States Federal Income Tax Consequences of the Reverse Stock Split

​

The following summary describes certain material U.S. federal income tax consequences of the Reverse Stock Split to holders of our common stock. This summary addresses the tax consequences only to a beneficial owner of our common stock that is (i) an individual who is a citizen or resident of the United States, (ii) a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof or the District of Columbia, (iii) an estate the income of which is subject to U.S. federal income taxation regardless of its source, or (iv) a trust if a U.S. court can exercise primary supervision over its administration and one or more U.S. persons have authority to control all of its substantial decisions, or that has a valid election in effect to be treated as a U.S. person (a “U.S. holder”). This summary does not address all of the tax consequences that may be relevant to any particular stockholder, including any state, local or foreign tax consequences or other tax considerations that arise from rules of general application that may be applicable to all taxpayers or to certain classes of taxpayers or any tax considerations that are generally assumed to be known by investors. This summary also does not address the tax consequences to persons who may be subject to special treatment under U.S. federal income tax law or persons that do not hold our common stock as “capital assets” (generally, property held for investment). This summary is based on the provisions of the Internal Revenue Code of 1986, as amended, the U.S. Treasury regulations promulgated thereunder, and related administrative rulings and judicial authority, all as in effect as of the date hereof. Subsequent developments in U.S. federal income tax law, including changes in law or differing interpretations, which may be applied retroactively, could have a material effect on the U.S. federal income tax consequences of the Reverse Stock Split.

If a partnership (or other entity classified as a partnership for U.S. federal income tax purposes) is the beneficial owner of our common stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner and the activities of the partnership, for federal income tax purposes. Partnerships that hold our common stock, and partners in such partnerships, should consult their own tax advisors regarding the U.S. federal income tax consequences of the Reverse Stock Split.

The Reverse Stock Split should generally be treated as a “recapitalization” for U.S. federal income tax purposes. Therefore, except with respect to the receipt of cash by certain holders in lieu of fractional shares (as discussed further below), no gain or loss should be recognized by a U.S. holder upon the Reverse Stock Split. Accordingly, the aggregate tax basis in the common stock received pursuant to the Reverse Stock Split should equal the aggregate tax basis in the common stock surrendered (excluding any portion of such basis that is allocated to any fractional share) and the holding period for the common stock received should include the holding period for the common stock surrendered. The U.S. Treasury regulations provide detailed rules for allocating the tax basis and holding period of the shares of our common stock surrendered for the shares of our common stock received pursuant to the Reverse Stock Split. U.S. holders of shares of our common stock acquired on different dates and at different prices should consult their tax advisors regarding the allocation of the tax basis and holding period of such shares.

A U.S. holder who receives cash in lieu of a fractional share of our common stock pursuant to the Reverse Stock Split should generally be treated as having received such fractional share and then as having received such cash in redemption of such fractional share. Such U.S. holder should generally recognize capital gain or loss equal to the difference between the amount of cash received and the portion of the U.S. holder’s tax basis in the pre-split shares surrendered that is allocable to such fractional share. Such capital gain or loss will be long-term capital gain or loss if the U.S. holder’s holding period for the pre-split shares surrendered exceeds one year at the Effective Time. In certain circumstances, including for a U.S. holder that actually or constructively owns a significant interest in the company, the cash received could be treated as a distribution taxable under Section 301 of the Internal Revenue Code. U.S. holders should consult their tax advisors regarding the tax treatment of any cash received in lieu of a fractional share.

​

39

Table of Contents

Each stockholder should consult his, her or its own tax advisor regarding the U.S. federal, state, local and foreign income and other tax consequences of the Reverse Stock Split.

THE BOARD RECOMMENDS A VOTE “FOR” THE APPROVAL OF THE REVERSE SPLIT AMENDMENT AND THE AUTHORIZATION OF THE BOARD TO DETERMINE THE RATIO AND EFFECT THE REVERSE STOCK SPLIT. APPROVAL OF PROPOSAL FOUR REQUIRES THAT THE VOTES CAST “FOR” THE PROPOSAL EXCEED THE VOTES CAST "AGAINST" THE PROPOSAL.

​

​

​

​

40

Table of Contents

ADDITIONAL INFORMATION

Householding of Annual Meeting Materials

Some banks, brokers and other nominee record holders may be participating in the practice of “householding” proxy statements and annual reports. This means that only one set of our proxy statement and 2025 Annual Report, may have been sent to multiple stockholders in your household. We will promptly deliver a separate copy of either document to you if you contact us at: Mustang Bio, Inc., 95 Sawyer Road, Suite 110, Waltham, Massachusetts 02453, Attn: Corporate Secretary. You may also contact us at (781) 652-4500.

If you want to receive separate copies of the proxy statement and annual report in the future, or if you are receiving multiple copies and would like to receive only one copy for your household, you should contact your bank, broker, or other nominee record holder, or you may contact us at the above address or phone number.

Stockholder Proposals for Our 2027 Annual Meeting

Only proper proposals under Rule 14a-8 of the Exchange Act which are timely received will be included in the proxy materials for our next annual meeting. In order to be considered timely, such proposal must be received by our Corporate Secretary at 95 Sawyer Road, Suite 110, Waltham, Massachusetts 02453, no later than August 4, 2027, the date that is 120 calendar days prior to the anniversary of the date of this year’s proxy statement. We suggest that stockholders submit any stockholder proposal by certified mail, return receipt requested. If a stockholder fails to provide timely notice of a proposal to be included in our proxy materials as described in this paragraph, and such proposal otherwise properly comes before the 2027 Annual Meeting of Stockholders, the proxies designated by our Board will have discretionary authority to vote on any such proposals.

Our Bylaws require stockholders to provide advance notice to the Company of any stockholder director nomination(s) and any other matter a stockholder wishes to present for action at an annual meeting of stockholders (other than matters to be included in our proxy statement, which are discussed in the previous paragraph). In order to properly bring business before an annual meeting, our Bylaws require, among other things, that the stockholder submit written notice thereof complying with our Bylaws to our Corporate Secretary, at the above address, not less than 50 days nor more than 90 days prior to the anniversary of the preceding year’s annual meeting. Therefore, the Company must receive notice of a stockholder proposal submitted other than pursuant to Rule 14a-8 (as discussed above) no sooner than September 22, 2027, and no later than November 1, 2027.

In addition to satisfying the foregoing requirements under the Company’s Bylaws, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than October 22, 2027.

Other Matters

Our Board does not know of any other matters that may come before the meeting. However, if any other matters are properly presented to the meeting, it is the intention of the persons named in the accompanying proxy card to vote, or otherwise act, in accordance with their judgment on such matters.

​

41

Table of Contents

Solicitation of Proxies

We will bear the cost of solicitation of proxies. In addition to the solicitation of proxies by mail, our officers and employees may solicit proxies in person or by telephone. We may reimburse brokers or persons holding stock in their names, or in the names of their nominees, for their expenses in sending proxies and proxy material to beneficial owners.

Incorporation of Information by Reference

The Audit Committee Report contained in this proxy statement is not deemed filed with the SEC and shall not be deemed incorporated by reference into any prior or future filings made by us under the Securities Act or the Exchange Act, except to the extent that we specifically incorporate such information by reference. Our Annual Report on Form 10-K for the year ended December 31, 2025, delivered to you together with this proxy statement, is hereby incorporated by reference.

​

42

​

APPENDIX A

​

CERTIFICATE OF AMENDMENT

TO

THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

OF

MUSTANG BIO, INC.

 

Mustang Bio, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify:

 

1.            The Amended and Restated Certificate of Incorporation of the Corporation, as amended, is hereby amended by inserting the following Subsection 9 to Article IV, Section A thereof:

 

“9.           Reverse Stock Split (2027).

 

9.1            Upon the filing and effectiveness (the “2027 Effective Time”), pursuant to the DGCL, of this Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Corporation, as amended, every [__] issued and outstanding shares or shares held by the Corporation as treasury stock of the Corporation’s common stock, par value $0.0001 per share, as of the date and time immediately preceding the 2027 Effective Time (the “Prior Shares”), shall automatically be reclassified as and converted into one (1) validly issued, fully paid and non-assessable share of common stock of the Corporation (the “New 2027 Shares”) without any further action by the Corporation or the holder thereof, subject to the treatment of fractional share interests as described below (the “2027 Reverse Stock Split”). Further, every right, option and warrant to acquire Prior Shares outstanding immediately prior to the 2027 Effective Time shall, as of the 2027 Effective Time and without any further action, automatically be reclassified into the right to acquire New 2027 Shares based on the conversion ratio of shares of Prior Shares to New 2027 Shares set forth in the preceding sentence, but otherwise upon the terms of such right, option or warrant (except that the exercise or purchase price of such right, option or warrant shall be proportionately adjusted).

 

No fractional shares shall be issued in connection with the 2027 Reverse Stock Split. Stockholders who otherwise would be entitled to receive fractional New 2027 Shares in the 2027 Reverse Stock Split shall be entitled to receive cash (without interest or deduction) from the Corporation’s transfer agent in lieu of such fractional share interests upon the submission of a letter of transmittal by a stockholder holding the shares in book-entry form and, where shares are held in certificated form, upon the surrender of the stockholder’s Prior Certificates (as defined below), in an amount equal to the product obtained by multiplying (a) the closing price per share of the Common Stock as reported on the Nasdaq Capital Market as of the date of the 2027 Effective Time, by (b) the fraction of one New 2027 Share owned by the stockholder.

 

9.2            Each holder of record of a certificate which immediately prior to the last trading day preceding the date of the 2027 Effective Time (the “2027 Effective Date”) represents Prior Shares (the “Prior Certificates”) shall be entitled to receive upon surrender of such Prior Certificates to the Corporation’s transfer agent for cancellation, a certificate (the “New 2027 Certificates”) representing the number of whole New 2027 Shares into and for which the shares formerly represented by such Prior Certificates so surrendered are exchangeable. From and after the 2027 Effective Date, Prior Certificates shall represent only the right to receive New 2027 Certificates pursuant to the provisions hereof.”

 

2.            The foregoing amendment was duly adopted in accordance with the provisions of Section 242 of the DGCL.

 

[Signature page follows.]

 

 

​

43

​

​

IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to the Corporation’s Amended and Restated Certificate of Incorporation, as amended, to be executed and acknowledged by its duly appointed officer as of this ___ day of _____________, 2027.

 

 

MUSTANG BIO, INC.

 

 

 

 

By:

  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

 

Name: Manuel Litchman, MD

 

Title: President, Chief Executive Officer and Interim Chief Financial Officer

​

44

​

GRAPHIC

Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. T05602-P59950 01) Michael S. Weiss 02) Adam J. Chill 03) Neil Herskowitz 04) David Jin 05) Manuel Litchman, M.D. 06) Lindsay A. Rosenwald, M.D. 07) Michael J. Zelefsky, M.D. For All Withhold All For All Except For Against Abstain For Against Abstain ! ! ! MUSTANG BIO, INC. Nominees: 2. Ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. 3. Approve the compensation of the Company's named executive officers, in an advisory vote. 4. Approve an amendment to the Company’s Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of the Company's issued and outstanding common stock within a range of between 1-for-5 and 1-for-30 (with the Company's board of directors being authorized to determine, at its discretion, the exact ratio and when to effect the reverse stock split). NOTE: In their discretion, the proxies are authorized to vote upon such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. This proxy, when properly executed, will be voted as directed herein by the undersigned stockholder. If no direction is made, the proxy will be voted in accordance with the Board of Directors’ recommendations and, accordingly, will be voted FOR each of the Board of Directors’ nominees for director specified in proposal 1 and FOR proposals 2, 3 and 4. 1. Election of seven directors to serve until the next Annual Meeting The Board of Directors recommends you vote FOR the following: The Board of Directors recommends you vote FOR the following proposal: The Board of Directors recommends you vote FOR the following proposal: ! ! ! To withhold authority to vote for any individual nominee(s), mark "For All Except" and write the number(s) of the nominee(s) on the line below. Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. The Board of Directors recommends you vote FOR the following proposal: For Against Abstain ! ! ! ! ! ! SCAN TO VIEW MATERIALS & VOTEw MUSTANG BIO, INC. 95 SAWYER ROAD, SUITE 110 WALTHAM, MA 02453 VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 P.M. ET on December 20, 2026. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. During The Meeting - Go to www.virtualshareholdermeeting.com/MBIO2026 You may attend the meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked by the arrow available and follow the instructions. VOTE BY PHONE - 1-800-690-6903 Use any touch-tone telephone to transmit your voting instructions. Vote by 11:59 P.M. ET on December 20, 2026. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717.

GRAPHIC

T05603-P59950 Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice and Proxy Statement and Annual Report are available at www.proxyvote.com. Continued and to be signed on reverse side MUSTANG BIO, INC. Annual Meeting of Stockholders December 21, 2026 10:00 AM, EST This proxy is solicited by the Board of Directors The stockholder(s) hereby appoint(s) Manuel Litchman, M.D. and Peter Carney, or either of them, as proxies, each with the power to appoint his substitute, and hereby authorize(s) them to represent and to vote, as designated on the reverse side of this ballot, all of the shares of (Common/Preferred) Stock of MUSTANG BIO, INC. that the stockholder(s) is/are entitled to vote at the Annual Meeting of Stockholders to be held at 10:00 AM, EST on Monday, December 21, 2026, virtually at www.virtualshareholdermeeting.com/MBIO2026, and any adjournment or postponement thereof. This proxy, when properly executed, will be voted in the manner directed herein. If no such direction is made, this proxy will be voted in accordance with the Board of Directors' recommendations.

Keep reading